



**Ethiopia**  
**Country Operational Plan**  
**FY 2015**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source	Applied Pipeline
	GAP	GHP-State	GHP-USAID	Total	
DOD		866,736		866,736	120,000
HHS/CDC	2,787,500	95,403,193		98,190,693	3,750,000
HHS/HRSA		1,150,000		1,150,000	0
State		634,000		634,000	0
State/AF		300,000		300,000	6,623,727
State/PRM		353,000		353,000	0
PC				0	1,891,023
USAID		73,505,571		73,505,571	6,534,180
<b>Total</b>	<b>2,787,500</b>	<b>172,212,500</b>	<b>0</b>	<b>175,000,000</b>	<b>18,918,930</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							On Hold Amount	Total
	State	DOD	HHS/CDC	HHS/HRSA	State/AF	State/PRM	USAID		
CIRC	6,414	39,000	212,783			0	42,316	0	300,513
HBHC	6,842	0	7,645,858			0	9,578,974	0	17,231,674
HKID	9,621					0	11,297,003	0	11,306,624
HLAB	5,345		3,355,837				805,486	0	4,166,668
HMBL	5,345	344,100	2,516,110					0	2,865,555
HMIN	6,414	0	16,892			0	114,197	0	137,503
HTXD	5,345								5,345
HTXS	6,200		46,252,259		0	0	17,211,791	0	63,470,250
HVAB	16,036						0	0	16,036
HVCT	18,174		4,092,721			0	3,228,619	0	7,339,514
HVMS	404,156	0	5,578,373				2,587,893	0	8,570,422
HVOP	23,518	383,636	3,751,737			153,000	10,712,355	0	15,024,246



HVSI	16,891	100,000	6,509,839			0	2,720,013	0	<b>9,346,743</b>
HVTB	16,036		3,819,562				1,657,454	0	<b>5,493,052</b>
IDUP	16,036								<b>16,036</b>
MTCT	18,174		3,976,951			200,000	2,232,424	0	<b>6,427,549</b>
OHSS	16,036		4,695,397	1,150,000	300,000		10,169,397	0	<b>16,330,830</b>
PDCS	16,036		1,179,926				440,028	0	<b>1,635,990</b>
PDTX	21,381		4,586,448				707,621	0	<b>5,315,450</b>
	<b>634,000</b>	<b>866,736</b>	<b>98,190,693</b>	<b>1,150,000</b>	<b>300,000</b>	<b>353,000</b>	<b>73,505,571</b>	<b>0</b>	<b>175,000,000</b>



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	16,846,409	0
HKID	11,042,134	0
HVTB	5,218,689	0
PDCS	1,432,409	0
<b>Total Technical Area Planned Funding:</b>	<b>34,539,641</b>	<b>0</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	3,822,485	0
HVSI	7,740,845	0
OHSS	15,669,802	0
<b>Total Technical Area Planned Funding:</b>	<b>27,233,132</b>	<b>0</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	258,000	0
HMBL	2,791,000	0
HMIN	107,248	0
HVAB	0	0
HVCT	7,117,095	0
HVOP	14,309,410	0
MTCT	6,095,866	0
<b>Total Technical Area Planned</b>	<b>30,678,619</b>	<b>0</b>



<b>Funding:</b>		
-----------------	--	--

**Technical Area: Treatment**

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXS	62,331,714	0
PDTX	5,125,275	0
<b>Total Technical Area Planned Funding:</b>	<b>67,456,989</b>	<b>0</b>

## Technical Area Summary Indicators and Targets

Indicator Number	Label	2015	2016
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	86 %	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,119,239	1,272,846
	Number of new ANC and L&D clients	1,305,316	1,347,052
	By: Known positives at entry	13,171	13,618
	By: Number of new positives identified	9,277	5,958
	Sum of Positives Status disaggregates	22,448	19,576
	Required only for DREAMS Countries - By Number of new positives: <15		0
	Required only for DREAMS Countries - By Number of new positives: 15-19		1
	Required only for DREAMS Countries - By Number of new positives: 20-24		2
	Required only for DREAMS Countries - By Number of new positives: 25+		6

	Required only for DREAMS Countries - By Number of known positives: <15		0
	Required only for DREAMS Countries - By Number of known positives: 15-19		0
	Required only for DREAMS Countries - By Number of known positives: 20-24		0
	Required only for DREAMS Countries - By Number of known positives: 25+		1
	Required only for DREAMS Countries - Denominator: <15		0
	Required only for DREAMS Countries - Denominator: <15-19		10
	Required only for DREAMS Countries - Denominator: 20-24		150
	Required only for DREAMS Countries - Denominator: 25+		912
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	92 %	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	75,521	64,385

	Number of new ANC and L&D clients	81,864	67,459
	By: Known positives at entry	921	579
	By: Number of new positives identified	836	421
	Sum of Positives Status disaggregates	1,757	1,000
	Required only for DREAMS countries - By known positives: <15		
	Required only for DREAMS countries - By known positives: 15-19		
	Required only for DREAMS countries - By known positives: 20-24		
	Required only for DREAMS countries - By known positives: 25+		
	Required only for DREAMS countries - By new positives: <15		
	Required only for DREAMS countries - By new positives: 15-19		
	Required only for DREAMS countries - By new positives: 20-24		
	Required only for DREAMS countries - By new positives: 25+		
	Required only for DREAMS countries - Denominator: <15		
	Required only for DREAMS countries - Denominator:		

	15-19		
	Required only for DREAMS countries - Denominator: 20-24		
	Required only for DREAMS countries - Denominator: 25+		
PMTCT_ARV_DSD	PMTCT_ARV_DSD Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD)	87 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	19,444	18,890
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	22,432	19,651
	Life-long ART (including Option B+)	19,444	
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	9,357	6,544
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	10,087	12,043

	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)		
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)		0
	Single-dose nevirapine (with or without tail)		0
	Sum of Regimen Type disaggregates	19,444	0
	Sum of New and Current disaggregates	19,444	18,587
PMTCT_ARV_TA	PMTCT_ARV_TA Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (TA)	96 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,695	1,447
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,757	1,522

	Life-long ART (including Option B+)	1,695	
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	725	471
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	970	549
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)		
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)		
	Single-dose nevirapine (with or without tail)		
	Sum of Regimen Type disaggregates	1,695	
	Sum of New and Current disaggregates	1,695	1,020
PMTCT_FO_DSD	PMTCT_FO_DSD Final outcomes among HIV exposed infants registered in the birth cohort	n/a	
	Number of HIV-exposed infants with a documented outcome by 18 months of age disaggregated by outcome type.		17,506
	Number of HIV-exposed infants registered in the birth		19,588

	cohort at any time between 0 and 18 months of age (including transfer-ins)		
	HIV-infected: Linked to ART		40
	HIV-infected: Not linked to ART		3
	HIV-infected: Unknown link		
	HIV-uninfected: Not breastfeeding		0
	HIV-uninfected: Still breastfeeding		0
	HIV-uninfected: Breastfeeding status unknown		0
	Other: In care but no test done		0
	Other: Lost to follow-up		0
	Other: Died		0
	Other: Transferred out		0
	PMTCT_FO_TA Final outcomes among HIV exposed infants registered in the birth cohort	n/a	
PMTCT_FO_TA	Number of HIV-exposed infants with a documented outcome by 18 months of age disaggregated by outcome type.		763
	Number of HIV-exposed infants registered in the birth cohort at any time between 0 and 18 months of age (including transfer-ins)		856
	HIV-infected: Linked to ART		

	HIV-infected: Not linked to ART		
	HIV-infected: Unknown link		
	HIV-uninfected: Breastfeeding status unknown		
	HIV-uninfected: Not breastfeeding		
	HIV-uninfected: Still breastfeeding		
	Other: Died		
	Other: In care but no test done		
	Other: Lost to follow-up		
	Other: Transferred out		
KP_MAT_DSD	KP_MAT_DSD Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a	
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months		0
	Sex: Male		0
	Sex: Female		0
	Sum of Sex disaggregates		0
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	53	50
	By AE type: Number of		

	VMMC clients with one or more moderate or severe surgical intra-operative AE(s)		
	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)		
	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)		
	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)		
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)		
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)		
	By AE Type: Number of		

	VMMC clients with one or more moderate or severe medical device-related AE(s)		
	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)		
	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)		
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	11,854	10,250
	By Age: <1	0	0
	By Age: 1-9	3,538	0
	By Age: 10-14	3,130	3,275
	By Age: 15-19	2,748	1,766
	By Age: 20-24	1,813	940
	By Age: 25-29		785
	By Age: 30-49		3,146
	By Age: 50+	10	138
	Sum of age disaggregates	11,854	6,119
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)		12

	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)		8,240
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site		1,998
	By circumcision technique: Surgical VMMC	1,500	10,050
	By circumcision technique: Device-based VMMC		0
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	1,500	10,195
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery		55
PrEP_NEW_TA	PrEP_NEW_TA Number of adult women and adolescent girls newly enrolled on oral or topical PrEP	n/a	
	Number of adult women and adolescent girls newly enrolled on oral or topical PrEP		40
	Estimated number of adolescent girls and young women (ages 15-24) in a		0

	district who are HIV-uninfected and at elevated risk of HIV infection, as evidence by program or other data		
	Numerator: Female 15-19		
	Numerator: Female 20-24		
	Denominator: 15-19		
	Denominator: 20-24		
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	629,341	542,920
	Total number of people in the target population		4,054,462
	Age/sex: 10-14 Male	3,962	221
	Age/sex: 15-19 Male	50,442	42,253
	Age/sex: 20-24 Male	58,737	148,838
	Age/sex: 25-49 Male	150,875	148,130
	Age/sex: 50+ Male	25,272	329
	Age/sex: 10-14 Female	26,989	1,644
	Age/sex: 15-19 Female	87,136	23,995
	Age/sex: 20-24 Female	67,467	40,849
	Age/sex: 25-49 Female	149,635	69,618
	Age/sex: 50+ Female	8,826	1,231

	Sum of Age/Sex disaggregates	629,341	477,108
PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only)	79 %	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	68,930	19,379
	Total number of people in the target population	87,035	23,130
	Age/sex: 10-14 Male		30
	Age/sex: 15-19 Male		24
	Age/sex: 20-24 Male		42
	Age/sex: 25-49 Male		197
	Age/sex: 50+ Male		284
	Age/sex: 10-14 Female		130
	Age/sex: 15-19 Female		61
	Age/sex: 20-24 Female		147
	Age/sex: 25-49 Female		703
	Age/sex: 50+ Female		643
	Sum of Age/Sex disaggregates		2,261
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based	n/a	

	on evidence and/or meet the minimum standards required (DSD)		
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	92,954	111,282
	Total estimated number of key population in the catchment area		221,987
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	92,954	104,725
	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		0
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations		0

	reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		0
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)		207,053
	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of		

	key population in the catchment area)		
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	632,480	623,575
	By Test Result: Negative	614,389	593,982
	By Test Result: Positive	18,091	16,575
	Sum of Test Result disaggregates	632,480	610,557
	Test Result by Age and Sex: Positive: <1 Male		18
	Test Result by Age and Sex:		72



	Positive: 1-4 Male		
	Test Result by Age and Sex: Positive: 5-9 Male		84
	Test Result by Age and Sex: Positive: 10-14 Male		41
	Test Result by Age and Sex: Positive: 15-19 Male		321
	Test Result by Age and Sex: Positive: 20-24 Male		1,172
	Test Result by Age and Sex: Positive: 25-49 Male		1,874
	Test Result by Age and Sex: Positive: 50+ Male		175
	Test Result by Age and Sex: Positive: <1 Female		15
	Test Result by Age and Sex: Positive: 1-4 Female		58
	Test Result by Age and Sex: Positive: 5-9 Female		69
	Test Result by Age and Sex: Positive: 10-14 Female		42
	Test Result by Age and Sex: Positive: 15-19 Female		1,572
	Test Result by Age and Sex: Positive: 20-24 Female		4,133
	Test Result by Age and Sex: Positive: 25-49 Female		1,675
	Test Result by Age and Sex: Positive: 50+ Female		486
	Test Result by Age and Sex: Negative: <1 Male		665
	Test Result by Age and Sex: Negative: 1-4 Male		1,920
	Test Result by Age and Sex:		2,148

	Negative: 5-9 Male		
	Test Result by Age and Sex: Negative: 10-14 Male		1,112
	Test Result by Age and Sex: Negative: 15-19 Male		24,121
	Test Result by Age and Sex: Negative: 20-24 Male		65,542
	Test Result by Age and Sex: Negative: 25-49 Male		148,057
	Test Result by Age and Sex: Negative: 50+ Male		8,940
	Test Result by Age and Sex: Negative: <1 Female		565
	Test Result by Age and Sex: Negative: 1-4 Female		1,520
	Test Result by Age and Sex: Negative: 5-9 Female		1,821
	Test Result by Age and Sex: Negative: 10-14 Female		1,112
	Test Result by Age and Sex: Negative: 15-19 Female		19,101
	Test Result by Age and Sex: Negative: 20-24 Female		91,784
	Test Result by Age and Sex: Negative: 25-49 Female		108,150
	Test Result by Age and Sex: Negative: 50+ Female		12,039
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	20,134	9,539
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	276,418	260,619
	Aggregated Age/sex - USE	50,922	10,942

	WITH HQ PERMISSION ONLY: <15 Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	285,006	248,294
	Sum of Aggregated Age/Sex <15	71,056	20,481
	Sum of Aggregated Age/Sex 15+	561,424	508,913
	Sum of Aggregated Age/Sex disaggregates	632,480	529,394
	Service Delivery Point by Result: Antenatal Clinic - All results		
	Service Delivery Point by Result: Antenatal Clinic - Positive		6
	Service Delivery Point by Result: Antenatal Clinic - Negative		2,344
	Service Delivery Point by Result: Labor & delivery - All results		210
	Service Delivery Point by Result: Labor & delivery - Positive		0
	Service Delivery Point by Result: Labor & delivery - Negative		210
	Service Delivery Point by Result: Under 5 Clinic – All results		74
	Service Delivery Point by Result: Under 5 Clinic - Positive		1

	Service Delivery Point by Result: Under 5 Clinic - Negative		73
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		10
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		0
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		10
	Service Delivery Point by Result: Tuberculosis – All results		76
	Service Delivery Point by Result: Tuberculosis - Positive		11
	Service Delivery Point by Result: Tuberculosis - Negative		65
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		620
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		8
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		612
	Service Delivery Point by Result: Outpatient Department – All Results		4,650
	Service Delivery Point by Result: Outpatient		6



	Department - Positive		
	Service Delivery Point by Result: Outpatient		4,644
	Department - Negative		
	Service Delivery Point by Result: Inpatient – All Results		700
	Service Delivery Point by Result: Inpatient - Positive		6
	Service Delivery Point by Result: Inpatient - Negative		694
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		100
	Service Delivery Point by Result: HIV care and treatment clinic - Positive		2
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		98
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		877
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		38
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		839
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by		1,328

	Result: Voluntary Counseling & Testing (co-located) - Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		43,365
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Positive		208
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Negative		23,498
	Service Delivery Point by Result: Mobile – All Results		279,689
	Service Delivery Point by Result: Mobile - Positive		5,102
	Service Delivery Point by Result: Mobile - Negative		269,187
	Service Delivery Point by Result: Home-based – All Results		250
	Service Delivery Point by Result: Home-based - Positive		3
	Service Delivery Point by Result: Home-based - Negative		247
	Service Delivery Point by		56

	Result: Other – All Results		
	Service Delivery Point by Result: Other - Positive		1
	Service Delivery Point by Result: Other - Negative		55
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,893,706	4,862,761
	By Test Result: Negative		4,490,912
	By Test Result: Positive		84,718
	Sum of Test Result disaggregates		4,575,630
	Test Result by Age and Sex: Positive: <1 Male		1,592
	Test Result by Age and Sex: Positive: 1-4 Male		1,772
	Test Result by Age and Sex: Positive: 5-9 Male		876
	Test Result by Age and Sex: Positive: 10-14 Male		15
	Test Result by Age and Sex: Positive: 15-19 Male		1,417
	Test Result by Age and Sex: Positive: 20-24 Male		18,799
	Test Result by Age and Sex: Positive: 25-49 Male		
	Test Result by Age and Sex: Positive: 50+ Male		3,319
	Test Result by Age and Sex: Positive: <1 Female		1,222
	Test Result by Age and Sex: Positive: 1-4 Female		1,511

	Test Result by Age and Sex: Positive: 5-9 Female		876
	Test Result by Age and Sex: Positive: 10-14 Female		43
	Test Result by Age and Sex: Positive: 15-19 Female		7,239
	Test Result by Age and Sex: Positive: 20-24 Female		33,979
	Test Result by Age and Sex: Positive: 25-49 Female		1,392
	Test Result by Age and Sex: Positive: 50+ Female		1,762
	Test Result by Age and Sex: Negative: <1 Male		45,733
	Test Result by Age and Sex: Negative: 1-4 Male		140,209
	Test Result by Age and Sex: Negative: 5-9 Male		157,221
	Test Result by Age and Sex: Negative: 10-14 Male		79,680
	Test Result by Age and Sex: Negative: 15-19 Male		24,393
	Test Result by Age and Sex: Negative: 20-24 Male		61,895
	Test Result by Age and Sex: Negative: 25-49 Male		1,039,124
	Test Result by Age and Sex: Negative: 50+ Male		117,769
	Test Result by Age and Sex: Negative: <1 Female		38,229
	Test Result by Age and Sex: Negative: 1-4 Female		109,074
	Test Result by Age and Sex: Negative: 5-9 Female		134,182

	Test Result by Age and Sex: Negative: 10-14 Female		79,537
	Test Result by Age and Sex: Negative: 15-19 Female		51,934
	Test Result by Age and Sex: Negative: 20-24 Female		355,753
	Test Result by Age and Sex: Negative: 25-49 Female		1,863,889
	Test Result by Age and Sex: Negative: 50+ Female		44,341
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male		429,993
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male		1,269,578
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female		366,324
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female		2,365,494
	Sum of Aggregated Age/Sex <15		796,317
	Sum of Aggregated Age/Sex 15+		3,635,072
	Sum of Aggregated Age/Sex disaggregates		4,431,389
	Service Delivery Point by Result: Antenatal Clinic - All results		
	Service Delivery Point by Result: Antenatal Clinic - Positive		

	Service Delivery Point by Result: Antenatal Clinic - Negative		
	Service Delivery Point by Result: Labor & delivery - All results		
	Service Delivery Point by Result: Labor & delivery - Positive		
	Service Delivery Point by Result: Labor & delivery - Negative		
	Service Delivery Point by Result: Under 5 Clinic – All results		
	Service Delivery Point by Result: Under 5 Clinic - Positive		
	Service Delivery Point by Result: Under 5 Clinic - Negative		
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		
	Service Delivery Point by Result: Tuberculosis – All results		
	Service Delivery Point by Result: Tuberculosis -		

	Positive		
	Service Delivery Point by Result: Tuberculosis - Negative		
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		
	Service Delivery Point by Result: Outpatient Department – All Results		
	Service Delivery Point by Result: Outpatient Department - Positive		
	Service Delivery Point by Result: Outpatient Department - Negative		
	Service Delivery Point by Result: Inpatient – All Results		
	Service Delivery Point by Result: Inpatient - Positive		
	Service Delivery Point by Result: Inpatient - Negative		
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		
	Service Delivery Point by Result: HIV care and treatment clinic - Positive		

	Service Delivery Point by Result: HIV care and treatment clinic - Negative		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - All		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Positive		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) -		

	Negative		
	Service Delivery Point by Result: Mobile – All Results		
	Service Delivery Point by Result: Mobile - Positive		
	Service Delivery Point by Result: Mobile - Negative		
	Service Delivery Point by Result: Home-based – All Results		17,547
	Service Delivery Point by Result: Home-based - Positive		345
	Service Delivery Point by Result: Home-based - Negative		17,202
	Service Delivery Point by Result: Other – All Results		
	Service Delivery Point by Result: Other - Positive		
	Service Delivery Point by Result: Other - Negative		
	Test Result by Aggregated Age and Sex: Negative <15 Male		
	Test Result by Aggregated Age and Sex: Negative 15+ Male		1,327
	Test Result by Aggregated Age and Sex: Negative <15 Female		
	Test Result by Aggregated Age and Sex: Negative 15+ Female		3,952

	Test Result by Aggregated Age and Sex: Positive <15 Male		
	Test Result by Aggregated Age and Sex: Positive 15+ Male		6
	Test Result by Aggregated Age and Sex: Positive <15 Female		
	Test Result by Aggregated Age and Sex: Positive 15+ Female		50
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a	
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.		34,468
	Total number of registered new and relapsed TB cases, during the reporting period.		35,365
	Sex: Male		579
	Sex: Female		576
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Status: Positive		255
	Status: Negative		900

TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a	
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.		29,854
	Total number of registered new and relapsed TB cases, during the reporting period.		30,690
	Age 15-19		
	Age: <1		0
	Age: 1-4		11
	Age: 10-14		14
	Age: 20+		1,711
	Age: 5-9		2
	Sex: Female		1,143
	Sex: Male		890
	Status: Negative		2,639
	Status: Positive		462
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	10,955	9,360
	Age/Sex: <10 Male		
	Age/Sex: 10-14 Male		36
	Age/Sex: 15-19 Male		1,872
	Age/Sex: 20-24 Male		2,840
	Age/Sex: 25+ Male		4,342
	Age/Sex: <10 Female		34
	Age/Sex: 10-14 Female		87

	Age/Sex: 15-19 Female		141
	Age/Sex: 20-24 Female		8
	Age/Sex: 25+ Female		
	By Age: 0-9	0	
	By Age: 10-14	0	
	By Age: 15-19	2,748	
	By Age: 20-24	2,749	
	By Age: 25+	5,498	
	Sum of Age disaggregates	10,995	
	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	60,000	55,296
	Age/Sex: <1 Male		275
	Age/Sex: 1-4 Male		2,181
	Age/Sex: 5-9 Male		6,747
	Age/Sex: 10-14 Male		7,297
	Age/Sex: 15-17 Male		4,165
	Age/Sex: 18-24 Male		751
	Age/Sex: 25+ Male		3,020
	Age/Sex: <1 Female		274
	Age/Sex: 1-4 Female		2,148
	Age/Sex: 5-9 Female		6,720
	Age/Sex: 10-14 Female		7,521
	Age/Sex: 15-17 Female		4,250
	Age/Sex: 18+ Female		
	Age/Sex: 18-24 Female		1,978
	Age/Sex: 25+ Female		7,969
	Sum of Age/Sex disaggregates		55,296
OVC_ACC_DSD	Number of active beneficiaries receiving		0
OVC_ACC_TA	Number of active beneficiaries receiving		0

	support from PEPFAR OVC programs to access HIV services		
	Age/Sex: <1 Male		0
	Age/Sex: 1-4 Male		0
	Age/Sex: 5-9 Male		0
	Age/Sex: 10-14 Male		0
	Age/Sex: 15-17 Male		0
	Age/Sex: 18-24 Male		0
	Age/Sex: 25+ Male		0
	Age/Sex: <1 Female		0
	Age/Sex: 1-4 Female		0
	Age/Sex: 5-9 Female		0
	Age/Sex: 10-14 Female		0
	Age/Sex: 15-17 Female		0
	Age/Sex: 18-24 Female		0
	Age/Sex: 25+ Female		0
	Sum of Age/Sex disaggregates		0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	455,000	509,065
	Age/Sex: <1 Male		2,131
	Age/Sex: 1-4 Male		17,370
	Age/Sex: 5-9 Male		52,865
	Age/Sex: 10-14 Male		56,969
	Age/Sex: 15-17 Male		32,448
	By: Age/sex: Male 18-24		10,250
	By: Age/sex: Male 25+		40,386
	Age/Sex: <1 Female		2,131
	Age/Sex: 1-4 Female		17,087

	Age/Sex: 5-9 Female		52,628
	Age/Sex: 10-14 Female		58,661
	Age/Sex: 15-17 Female		32,937
	By: Age/sex: 18-24 Female		26,764
	By: Age/sex: 25+ Female		106,301
	Sum of Age/Sex disaggregates		325,227
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+		



	Required only for DREAMS countries - By service, age and sex: Education Support Male <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver		



	Programs Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 5-9		
	Required only for DREAMS countries - By service, age		



	and sex: Parenting/Caregiver Programs Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17		
	Required only for DREAMS		

	countries - By service, age and sex: Social Protection Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+		



	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+		50
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1		
	Required only for DREAMS countries - By service, age and sex: Economic		

	Strengthening Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Economic		
	Strengthening Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Economic		
	Strengthening Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Economic		
	Strengthening Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Economic		
	Strengthening Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Economic		
	Strengthening Male 25+		
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS		0
	Age/Sex: <1 Male		0
	Age/Sex: 1-4 Male		0
	Age/Sex: 5-9 Male		0
	Age/Sex: 10-14 Male		0
	Age/Sex: 15-17 Male		0
	By age/sex: 18-24 Male		0
	By age/sex: 25+ Male		0
	Age/Sex: <1 Female		0

	Age/Sex: 1-4 Female		0
	Age/Sex: 5-9 Female		0
	Age/Sex: 10-14 Female		0
	Age/Sex: 15-17 Female		0
	By age/sex: 18-24 Female		0
	By age/sex: 25+ Female		0
	Sum of Age/Sex disaggregates		0
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Education		

	Support Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female <1		
	Required only for DREAMS		



	countries: By Service Area, age and sex: Parenting/Caregiver Program Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male <1		
	Required only for DREAMS countries: By Service Area,		



	age and sex: Parenting/Caregiver Program Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 1-4		



	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Social		

	Protection Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 15-17		
	Required only for DREAMS countries: By Service Area,		



	age and sex: Economic Strengthening Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 25+		
	Required only for DREAMS		

	countries: By Service Area, age and sex: Other Service Areas Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 25+		
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	469,965	456,285
	Age/sex: <1 Male		1,577

	Age/sex: 1-4 Male		5,297
	Age/sex: 5-9 Male		5,917
	Age/sex: 10-14 Male		3,264
	Age/sex: 15-19 Male		4,276
	Age/sex: 20-24 Male		5,093
	Age/sex: 25-49 Male		118,019
	Age/sex: 50+ Male		26,112
	Age/sex: <1 Female		1,263
	Age/sex: 1-4 Female		4,700
	Age/sex: 5-9 Female		5,667
	Age/sex: 10-14 Female		3,960
	Age/sex: 15-19 Female		4,614
	Age/sex: 20-24 Female		19,392
	Age/sex: 25-49 Female		200,948
	Age/sex: 50+ Female		22,107
	Sun of Age/Sex disaggregates		432,206
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	18,105	33
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	178,736	235
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	16,618	33
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	256,506	340
	Sum of Aggregated Age/Sex disaggregates	469,965	641
CARE_CURR_TA	Number of HIV positive adults and children who	7,233	17,765

	received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age/sex: <1 Male		7
	Age/sex: 1-4 Male		28
	Age/sex: 5-9 Male		32
	Age/sex: 10-14 Male		16
	Age/sex: 15-19 Male		115
	Age/sex: 20-24 Male		136
	Age/sex: 25-49 Male		3,253
	Age/sex: 50+ Male		729
	Age/sex: <1 Female		5
	Age/sex: 1-4 Female		23
	Age/sex: 5-9 Female		28
	Age/sex: 10-14 Female		19
	Age/sex: 15-19 Female		119
	Age/sex: 20-24 Female		537
	Age/sex: 25-49 Female		5,745
	Age/sex: 50+ Female		613
	Sum of Age/Sex disaggregates		11,405
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	879	0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,029	0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	719	0
	Aggregated Age/sex - USE	3,606	1

	WITH HQ PERMISSION ONLY: 15+ Female		
	Sum of Aggregated Age/Sex disaggregates	7,233	1
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	85,744	68,286
	Age/sex: <1 Male		327
	Age/sex: 1-4 Male		1,120
	Age/sex: 5-9 Male		1,285
	Age/sex: 10-14 Male		613
	Age/sex: 15-19 Male		874
	Age/sex: 20-24 Male		1,585
	Age/sex: 25-49 Male		18,475
	Age/sex: 50+ Male		2,710
	Age/sex: <1 Female		280
	Age/sex: 1-4 Female		852
	Age/sex: 5-9 Female		1,103
	Age/sex: 10-14 Female		617
	Age/sex: 15-19 Female		1,532
	Age/sex: 20-24 Female		4,387
	Age/sex: 25-49 Female		25,131
	Age/sex: 50+ Female		2,456
	Sum of Age/sex disaggregates		63,347
	Aggregated Age/sex: <15 Male	2,662	6

	Aggregated Age/sex: 15+ Male	31,810	44
	Aggregated Age/sex: <15 Female	2,429	53
	Aggregated Age/sex: 15+ Female	48,843	33
	Sum of Aggregated Age/sex disaggregates	85,744	136
CARE_NEW_TA	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		2,611
	Age/sex: <1 Female		1
	Age/sex: 1-4 Female		2
	Age/sex: 5-9 Female		3
	Age/sex: 10-14 Female		2
	Age/sex: 15-19 Female		39
	Age/sex: 20-24 Female		116
	Age/sex: 25-49 Female		652
	Age/sex: 50+ Female		63
	Age/sex: <1 Male		1
	Age/sex: 1-4 Male		7
	Age/sex: 5-9 Male		3
	Age/sex: 10-14 Male		2
	Age/sex: 15-19 Male		23
	Age/sex: 20-24 Male		44
	Age/sex: 25-49 Male		479
Age/sex: 50+ Male		71	

	Aggregated Age/sex: <15 Female		0
	Aggregated Age/sex: <15 Male		0
	Aggregated Age/sex: 15+ Female		0
	Aggregated Age/sex: 15+ Male		0
	Sum of Aggregated Age/sex disaggregates	85,744	136
	Sum of age/sex disaggregates		1,508
FN_THER_DSD	FN_THER_DSD Proportion of clinically undernourished PLHIV who received therapeutic or supplementary food	89 %	
	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	58,637	10,767
	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	65,901	40,629
	Age: <1	0	29
	Age: 1-4	3,599	198
	Age: 5-14	4,042	374
	Age: 15-17	848	159
	Age: 18+	50,148	8,577
	Sum of Age disaggregates	58,637	9,337
	Aggregated Age: <18	8,489	5
	Aggregated Age: 18+	50,148	5

	Sum of Aggregated Age disaggregates	58,637	10
	By Pregnancy/Postpartum Status: Pregnant		1
	By Pregnancy/Postpartum Status: Postpartum		1
FN_THER_TA	FN_THER_TA Proportion of clinically undernourished PLHIV who received therapeutic or supplementary food	n/a	
	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.		1
	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.		2
	Age: <1		0
	Age: 1-4		0
	Age: 5-14		0
	Age: 15-17		0
	Age: 18+		0
	Sum of Age disaggregates		0
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <18		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 18+		
	By Pregnancy/Postpartum Status: Pregnant		

	By Pregnancy/Postpartum Status: Postpartum		
	Sum of Aggregated Age disaggregates		
TB_IPT_DSD	TB_IPT_DSD Proportion of PLHIV newly enrolled in HIV clinical care who start isoniazid preventive therapy (IPT)	n/a	
	The number of PLHIV newly enrolled in HIV care who start IPT during the reporting period		18,561
	Number of HIV-positive adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: <15		
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: 15+		

	Sex: Male		
	Sex: Female		0
TB_IPT_TA	TB_IPT_TA Proportion of PLHIV newly enrolled in HIV clinical care who start isoniazid preventive therapy (IPT)	n/a	
	The number of PLHIV newly enrolled in HIV care who start IPT during the reporting period		12,036
	Number of HIV-positive adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age: <1		7
	Age: 1-4		32
	Age: 5-9		5
	Age: 10-14		11
	Age: 15-19		4
	Age: 20+		301
	Sum of Age disaggregates		360
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: <15		
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: 15+		
	Sex: Male		232

	Sex: Female		386
FN_ASSESS_DSD	FN_ASSESS_DSD Proportion of PLHIV who were nutritionally assessed via anthropometric measurement	n/a	
	The number of PLHIV who were nutritionally assessed via anthropometric measurement		410,967
	Number of HIV positive adults and children who received care and treatment services		455,698
	Age: <1		2,379
	Age: 1-4		8,080
	Age: 5-14		14,665
	Age: 15-17		7,066
	Age: 18+ years		324,091
	Sum of Age disaggregates		356,281
	Age (Aggregated) - USE WITH HQ PERMISSION ONLY <18		1,466
	Age (Aggregated) - USE WITH HQ PERMISSION ONLY 18+		13,433
	By Pregnancy/Postpartum Status: Pregnant		2
	By Pregnancy/Postpartum Status: Postpartum		2
	FN_ASSESS_TA	FN_ASSESS_TA Proportion of PLHIV who were nutritionally assessed via anthropometric measurement	n/a

	The number of PLHIV who were nutritionally assessed via anthropometric measurement		10,301
	Number of HIV positive adults and children who received care and treatment services		11,429
	Age: <1		13
	Age: 1-4		47
	Age: 5-14		90
	Age: 15-17		211
	Age: 18+ years		9,913
	Sum of Age disaggregates		10,274
	Age (Aggregated) - USE WITH HQ PERMISSION ONLY <18		
	Age (Aggregated) - USE WITH HQ PERMISSION ONLY 18+		
	By Pregnancy/Postpartum Status: Pregnant		
	By Pregnancy/Postpartum Status: Postpartum		
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	100 %	
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	7,579	6,235
	The number of registered	7,579	6,235

	new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period		
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		
	Male		125
	Female		131
	Sum of Sex disaggregates		256
	Newly tested		
	Known HIV-positive		
	Sum of Test Status disaggregates		
	Aggregated Age: <15		
	Aggregated Age: 15+		
	Sum of Aggregated Age disaggregates		
	Timeliness: Art initiation <8 weeks of start of TB treatment		
	Timeliness: Art initiation >8 weeks of start of TB treatment		
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a	
	The number of registered		4,853

	new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period		
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period		4,885
	Age: <1		0
	Age: 1-4		0
	Age: 5-9		0
	Age: 10-14		0
	Age: 15-19		7
	Age: 20+		350
	Sum of Age disaggregates		357
	Aggregated Age: <15		
	Aggregated Age: 15+		
	Sum of Aggregated Age disaggregates		
	Male		161
	Female		232
	Sum of Sex disaggregates		393
	Known HIV-positive		
	Newly tested		
	Sum of Test Status disaggregates		
	Timeliness: Art initiation <8 weeks of start of TB treatment		
	Timeliness: Art initiation >8 weeks of start of TB		

	treatment		
TB_OUTCOME_DSD	TB_OUTCOME_DSD TB treatment outcomes among registered new and relapsed TB cases who are HIV-positive	n/a	
	Aggregated outcomes of TB treatment among registered new and relapsed TB cases who are HIV-positive in the treatment cohort		255
	The total number of registered new and relapsed TB cases who are HIV-positive registered in the treatment cohort		255
	Outcome by Age: Cured <1		
	Outcome by Age: Cured 1-4		
	Outcome by Age: Cured 5-9		
	Outcome by Age: Cured 10-14		
	Outcome by Age: Cured: 15-19		
	Outcome by Age: Cured 20+		
	Outcome by Age: Treatment Complete <1		
	Outcome by Age: Treatment Complete 1-4		
	Outcome by Age: Treatment Complete 5-9		
	Outcome by Age: Treatment Complete 10-14		
	Outcome by Age: Treatment Complete 15-19		



	Outcome by Age: Treatment Complete 20+		
	Outcome by Age: Treatment Failed <1		
	Outcome by Age: Treatment Failed 1-4		
	Outcome by Age: Treatment Failed 5-9		
	Outcome by Age: Treatment Failed 10-14		
	Outcome by Age: Treatment Failed 15-19		
	Outcome by Age: Treatment Failed 20+		
	Outcome by Age: Died <1		
	Outcome by Age: Died 1-4		
	Outcome by Age: Died 5-9		
	Outcome by Age: Died 10-14		
	Outcome by Age: Died 15-19		
	Outcome by Age: Died 20+		
	Outcome by Age: Lost to Follow-up <1		
	Outcome by Age: Lost to Follow-up 1-4		
	Outcome by Age: Lost to Follow-up 5-9		
	Outcome by Age: Lost to Follow-up 10-14		
	Outcome by Age: Lost to Follow-up 15-19		
	Outcome by Age: Lost to Follow-up 20+		
	Outcome by Age: Not Evaluated <1		



	Outcome by Age: Not Evaluated 1-4		
	Outcome by Age: Not Evaluated 5-9		
	Outcome by Age: Not Evaluated 10-14		
	Outcome by Age: Not Evaluated 15-19		
	Outcome by Age: Not Evaluated 20+		
	Outcome by Sex: Treatment Complete Female		
	Outcome by Sex: Treatment Complete Male		8
	Outcome by Sex: Cured Female		
	Outcome by Sex: Cured Male		
	Outcome by Sex: Treatment failed Female		
	Outcome by Sex: Treatment failed Male		
	Outcome by Sex: Died Female		
	Outcome by Sex: Died Male		
	Outcome by Sex: Lost to Follow-up Female		
	Outcome by Sex: Lost to Follow-up Male		
	Outcome by Sex: Not Evaluated Female		
	Outcome by Sex: Not Evaluated Male		
TB_OUTCOME_TA	TB_OUTCOME_TA TB	n/a	

	treatment outcomes among registered new and relapsed TB cases who are HIV-positive		
	Aggregated outcomes of TB treatment among registered new and relapsed TB cases who are HIV-positive in the treatment cohort		461
	The total number of registered new and relapsed TB cases who are HIV-positive registered in the treatment cohort		486
	Outcome by Age: Cured <1		
	Outcome by Age: Cured 1-4		
	Outcome by Age: Cured 5-9		
	Outcome by Age: Cured 10-14		
	Outcome by Age: Cured 15-19		11
	Outcome by Age: Cured 20+		373
	Outcome by Sex: Cured Female		
	Outcome by Sex: Cured Male		
	Outcome by Age: Treatment Complete <1		
	Outcome by Age: Treatment Complete 1-4		
	Outcome by Age: Treatment Complete 5-9		
	Outcome by Age: Treatment Complete 10-14		



	Outcome by Age: Treatment Complete 15-19		
	Outcome by Age: Treatment Complete 20+		
	Outcome by Sex: Treatment Complete Female		
	Outcome by Sex: Treatment Complete Male		
	Outcome by Age: Treatment Failed <1		
	Outcome by Age: Treatment Failed 1-4		
	Outcome by Age: Treatment Failed 5-9		
	Outcome by Age: Treatment Failed 10-14		
	Outcome by Age: Treatment Failed 15-19		
	Outcome by Age: Treatment Failed 20+		
	Outcome by Sex: Treatment Failed Female		
	Outcome by Sex: Treatment Failed Male		
	Outcome by Age: Died <1		
	Outcome by Age: Died 1-4		
	Outcome by Age: Died 5-9		
	Outcome by Age: Died 10-14		
	Outcome by Age: Died 15-19		
	Outcome by Age: Died 20+		
	Outcome by Sex: Died Female		
	Outcome by Sex: Died Male		
	Outcome by Age: Lost to		

	Follow-up <1		
	Outcome by Age: Lost to Follow-up 1-4		
	Outcome by Age: Lost to Follow-up 5-9		
	Outcome by Age: Lost to Follow-up 10-14		
	Outcome by Age: Lost to Follow-up 15-19		
	Outcome by Age: Lost to Follow-up 20+		
	Outcome by Sex: Lost to Follow-up Female		
	Outcome by Sex: Lost to Follow-up Male		
	Outcome by Age: Not Evaluated <1		
	Outcome by Age: Not Evaluated 1-4		
	Outcome by Age: Not Evaluated 5-9		
	Outcome by Age: Not Evaluated 10-14		
	Outcome by Age: Not Evaluated 15-19		
	Outcome by Age: Not Evaluated 20+		
	Outcome by Sex: Not Evaluated Female		
	Outcome by Sex: Not Evaluated Male		
TB_SCREEN_DSD	TB_SCREEN_DSD Percentage of PLHIV who were screened for TB	89 %	

	symptoms at the last clinical visit to an HIV care facility during the reporting period.		
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	420,253	252,266
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	469,965	456,285
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+		
	Sum of Aggregated Age disaggregates		
	Sex: Male		
	Sex: Female		
	Sum of Sex disaggregates		
TB_SCREEN_TA	TB_SCREEN_TA	n/a	

	Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.		
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period		227,994
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	7,233	17,765
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		30
	Sum of Age disaggregates		30
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+		
	Sum of Aggregated Age disaggregates		
	Sex: Female		4,188
	Sex: Male		2,712

	Sum of Sex disaggregates		6,900
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	73 %	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	16,350	17,553
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	22,432	
	By infants who received a virologic test within 2 months of birth		13,951
	By infants who received their first virologic HIV test between 2 and 12 months of age		3,528
	Sum of Infant Age disaggregates		17,479
	By infants with a positive virologic test result within 12 months of birth		
	Number of infants with a positive virological test result within 2 months of birth		215
	Number of infants with a positive virological test result within 12 months of birth		313
	PMTCT_EID_TA	PMTCT_EID_TA Percent of	n/a

	infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)		
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period		973
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)		
	By infants who received a virologic test within 2 months of birth		497
	By infants who received their first virologic HIV test between 2 and 12 months of age		149
	Sum of Infant Age disaggregates		646
	By infants with a positive virologic test result within 12 months of birth		
	Number of infants with a positive virological test result within 2 months of birth		2
	Number of infants with a positive virological test result within 12 months of birth		5
PMTCT_CTX_DSD	PMTCT_CTX_DSD Percentage of infants born to HIV-positive pregnant women who were started on	n/a	

	cotrimoxazole (CTX) prophylaxis within two months of birth		
	Number of infants born to HIV-infected women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth within the reporting period		55
	Number of HIV-positive pregnant women identified in the reporting period (include known HIV- positive at entry)		
CARE_COMM_DSD	Number of HIV-infected adults and children receiving care and support services outside of the health facility		188,275
	Age/Sex: <1 Male		13
	Age/Sex: 1-4 Male		805
	Age/Sex: 5-9 Male		1,843
	Age/Sex: 10-14 Male		5,825
	Age/Sex: 15-19 Male		7,640
	Age/Sex: 20-24 Male		8,995
	Age/Sex: 25-49 Male		41,620
	Age/Sex: 50+ Male		5,018
	Age/Sex: <1 Female		22
	Age/Sex: 1-4 Female		1,180
	Age/Sex: 5-9 Female		2,324
	Age/Sex: 10-14 Female		6,388
	Age/Sex: 15-19 Female		9,263
	Age/Sex: 20-24 Female		17,932
	Age/Sex: 25-49 Female		72,114
Age/Sex: 50+ Female		7,014	
CARE_COMM_TA	Number of HIV-infected		38,857

	adults and children receiving care and support services outside of the health facility		
	Age/Sex: <1 Female		
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Female		
	Age/Sex: 1-4 Male		
	Age/Sex: 10-14 Female		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-19 Female		
	Age/Sex: 15-19 Male		
	Age/Sex: 20-24 Female		3,319
	Age/Sex: 20-24 Male		1,142
	Age/Sex: 25-49 Female		24,209
	Age/Sex: 25-49 Male		3,858
	Age/Sex: 5-9 Female		
	Age/Sex: 5-9 Male		
	Age/Sex: 50+ Female		4,188
	Age/Sex: 50+ Male		1,032
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	443,944	430,656
	Age/Sex: <1 Male	1,173	1,668
	Age/Sex: 1-4 Male	3,556	5,659
	Age/Sex: 5-14 Male	12,471	9,638
	Age/Sex: 15-19 Male		2,309
	Age/Sex: 20+ Male		136,783
	Age/Sex: <1 Female	1,152	1,322
	Age/Sex: 1-4 Female	3,422	4,995
	Age/Sex: 5-14 Female	11,440	10,021
	Age/Sex: 15-19 Female		5,460
	Age/Sex: 20+ Female		250,607

	Aggregated Age/Sex: <1 Male	1,173	13
	Aggregated Age/Sex: <1 Female	1,152	18
	Aggregated Age/Sex: 15+ Male	163,887	130
	Aggregated Age/Sex: 1-14 Female		10
	Aggregated Age/Sex: 15+ Female	246,843	159
	Sum of Aggregated Age/Sex <15	33,214	
	Sum of Aggregated Age/Sex 15+	410,730	289
	Sum of Aggregated Age/Sex disaggregates	443,944	289
	Aggregated Age/Sex: 1-14 Male		9
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	2,325	50
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	5,463	16,874
	Age/Sex: <1 Male		8
	Age/Sex: 1-4 Male		30
	Age/Sex: 5-14 Male		48
	Age/Sex: 15-19 Male		59
	Age/Sex: 20+ Male		3,611
	Age/Sex: <1 Female		5
	Age/Sex: 1-4 Female		26
	Age/Sex: 5-14 Female		53
	Age/Sex: 15-19 Female		139
	Age/Sex: 20+ Female		6,945

	Sum of Age/Sex disaggregations		10,924
	Aggregated Age/Sex: <1 Male		
	Aggregated Age/Sex: <1 Female		
	Aggregated Age/Sex: 1-14 Male		
	Aggregated Age/Sex: 15+ Male	1,982	
	Aggregated Age/Sex: 1-14 Female		
	Aggregated Age/Sex: 15+ Female	3,481	
	Sum of Aggregated Age/Sex <15		
	Sum of Aggregated Age/Sex 15+	5,463	
	Sum of Aggregated Age/Sex disaggregates	5,463	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15		
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	84,707	69,811
	By Age/Sex: <1 Male	371	365
	By Age/Sex: 1-4 Male	1,114	1,237
	By Age/Sex: 5-9 Male	1,825	1,415
	By Age/Sex: 10-14 Male	2,018	649
	By Age/Sex: 15-19 Male	1,212	313
	By Age/Sex: 20-24 Male	2,548	1,222
	By Age/Sex: 25-49 Male	22,460	18,210
	By Age/Sex: 50+ Male	1,907	2,056
	By Age/Sex: <1 Female	352	313

	By Age/Sex: 1-4 Female	1,054	928
	By Age/Sex: 5-9 Female	1,735	1,262
	By Age/Sex: 10-14 Female	621	651
	By Age/Sex: 15-19 Female	5,438	867
	By Age/Sex: 20-24 Female	10,889	6,503
	By Age/Sex: 25-49 Female	29,083	32,058
	By Age/Sex: 50+ Female	2,080	740
	Sum of Age/Sex disaggregates	84,707	68,789
	Aggregated Grouping by Age: <1 Male	371	11
	Aggregated Grouping by Age/Sex: 1-14 Male		0
	Aggregated Grouping by Age/Sex: 15+ Male	28,127	72
	Aggregated Grouping by Age/Sex: <1 Female	352	17
	Aggregated Grouping by Age/Sex: 15+ Female	47,490	84
	Sum of Aggregated Age/Sex disaggregates	84,707	156
	Pregnancy status		22
	Breastfeeding status		20
	Aggregated Grouping by Age/Sex: 1-14 Female		1
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)		2,710
	By Age/Sex: <1 Male		1
	By Age/Sex: 1-4 Male		7
	By Age/Sex: 5-9 Male		5
	By Age/Sex: 10-14 Male		2
	By Age/Sex: 15-19 Male		8

	By Age/Sex: 20-24 Male		29
	By Age/Sex: 25-49 Male		428
	By Age/Sex: 50+ Male		48
	By Age/Sex: <1 Female		1
	By Age/Sex: 1-4 Female		2
	By Age/Sex: 5-9 Female		5
	By Age/Sex: 10-14 Female		2
	By Age/Sex: 15-19 Female		18
	By Age/Sex: 20-24 Female		166
	By Age/Sex: 25-49 Female		866
	By Age/Sex: 50+ Female		17
	Sum of Age/Sex disaggregates		1,605
	Aggregated Grouping by Age: <1 Male		
	Aggregated Grouping by Age/Sex: 1-14 Male		
	Aggregated Grouping by Age/Sex: 15+ Male		
	Aggregated Grouping by Age: <1 Female		
	Aggregated Grouping by Age/Sex: 1-14 Female		
	Aggregated Grouping by Age/Sex: 15+ Female		
	Sum of Aggregated Age/Sex disaggregates		
	Pregnancy status		
	Breastfeeding status		
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of	82 %	

	antiretroviral therapy		
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	74,982	50,292
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	91,268	59,498
	Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		1,371
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		1,368
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		231
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating		14,866

	ART)		
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		907
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		1,367
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		256
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		26,783
	Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		1,640
	Age/Sex: 5-14 Male		1,636

	(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		285
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		17,644
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have		1,095

	died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		1,637
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		307
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		31,810
	Numerator by Status: Pregnant		24
	Numerator by Status:		21

	Breastfeeding		
	Denominator by Status: Pregnant		24
	Denominator by Status: Breastfeeding		21
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART		2,494
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up		2,933
	Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		42
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		42
	Age/Sex: 15-19 Male		7

	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		453
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		30
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		42
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		7
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		851
	Age/Sex: <5 Male		52

	(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		52
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		8
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have		529

	died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		32
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		52
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		8
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who		997

	initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Numerator by Status: Pregnant		
	Numerator by Status: Breastfeeding		
	Denominator by Status: Pregnant		
	Denominator by Status: Breastfeeding		
TX_VIRAL_DSD	TX_VIRAL_DSD Percentage of ART patients with an undetectable viral load at 12 months after initiation of ART	n/a	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record within the past 12 months		227
	Number of adults and children on ART at least 6 months whose medical records were reviewed		227
	Age/Sex: <1 Male		12
	Age/Sex: 1-4 Male		4
	Age/Sex: 5-14 Male		3
	Age/Sex: 15-19 Male		20
	Age/Sex: 20+ Male		63
	Age/Sex: <1 Female		17
	Age/Sex: 1-4 Female		4

	Age/Sex: 5-14 Female		4
	Age/Sex: 15-19 Female		27
	Age/Sex: 20+ Female		74
	Results Category: Undetectable		153
	Results Category: Detectable		63
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	28	91
LAB_ACC_TA	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation		8
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	1,628	2,173
	By clinical laboratories	1,564	2,059
	By Point-of-care testing sites	64	114
LAB_CAP_TA	Number of PEPFAR-supported testing		162

	facilities with capacity to perform clinical laboratory tests		
	By clinical laboratories		0
	By Point-of-care testing sites		0
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program		
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing		8,746
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program		5,682
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program		5,682
	CD4: Number of laboratories that perform this testing		471
	CD4: Number of laboratories that participate in this PT program		279
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program		279

	Early infant diagnostics: Number of laboratories that perform this testing		23
	Early infant diagnostics: Number of laboratories that participate in this PT program		23
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program		23
	HIV viral load: Number of laboratories that perform this testing		23
	HIV viral load: Number of laboratories that participate in this PT program		23
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program		23
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing		1,661
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program		290
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful		290

	passing criteria in this PT program		
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing		146
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program		25
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program		25
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing		16
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program		3
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program		3
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency		

	testing (PT) program		
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program		0
	CD4: Number of laboratories that participate in this PT program		0
	CD4: Number of laboratories that perform this testing		0
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program		0
	Early infant diagnostics: Number of laboratories that participate in this PT program		0
	Early infant diagnostics: Number of laboratories that perform this testing		0
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program		0
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program		0
	HIV serologic/diagnostic testing: Number of laboratories that perform this		0

	testing		
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program		0
	HIV viral load: Number of laboratories that participate in this PT program		0
	HIV viral load: Number of laboratories that perform this testing		0
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program		0
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program		0
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing		0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program		0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate		0

	in this PT program		
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing		0
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program		0
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program		0
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing		0
TX_UNDETECT_DSD	TX_UNDETECT_DSD Proportion of viral load tests with an undetectable viral load (<1000 copies/ml)	n/a	
	Number of viral load tests from adult and pediatric ART patients conducted in the past 12 months with a viral load <1,000 copies/ml		372
	Number of viral load tests performed from adults and children on ART within the current reporting period		376
	Age/Sex: <1 Male		15
	Age/Sex: 1-4 Male		4

	Age/Sex: 5-14 Male		7
	Age/Sex: 15-19 Male		37
	Age/Sex: 20+ Male		89
	Age/Sex: <1 Female		18
	Age/Sex: 1-4 Female		4
	Age/Sex: 5-14 Female		7
	Age/Sex: 15-19 Female		47
	Age/Sex: 20+ Female		111
	Pregnant		26
	Breastfeeding		22
	Test indication: Routine monitoring		109
	Test indication: Targeted monitoring		
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	9,117	14,058
	By Graduates: Doctors	1,399	1,016
	By Graduates: Nurses	734	499
	By Graduates: Midwives	2,930	2,549
	By Graduates: Social service workers	1,870	1,820
	By Graduates: Laboratory professionals	0	0
	By Graduates: Other	2,184	7,300
	Sum of Graduates disaggreagtes	9,117	13,184
FPINT_SITE_DSD	FPINT_SITE_DSD Family Planning and HIV	63 %	

	Integration: Percentage of HIV service delivery points supported by PEPFAR that are directly providing integrated voluntary family planning services		
	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	1,476	12
	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	2,342	12
	Service delivery type: Care and Support		
	Service delivery type: Treatment		
	Service delivery type: PMTCT		
	Sum of Service delivery type (Care, Tx and PMTCT) disaggregates		
FPINT_SITE_TA	FPINT_SITE_TA Family Planning and HIV Integration: Percentage of HIV service delivery points supported by PEPFAR that are directly providing integrated voluntary family planning services	n/a	
	Number of service delivery points supported by PEPFAR		1

	for HIV services that are directly providing integrated voluntary family planning services		
	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment		1
	Service delivery type: Care and Support		
	Service delivery type: Treatment		
	Service delivery type: PMTCT		
	Sum of Service Delivery Type (Care, Tx and PMTCT) disaggregates		

## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7515	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	566,736
10515	Clinical and Laboratory Standards Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	90,000
10517	Hawassa University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	515,000
10534	Federal Ministry of Health, Ethiopia	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
10548	Jimma University	University	U.S. Department of Health and Human Services/Centers	GHP-State	600,000

			for Disease Control and Prevention		
10557	Mekele University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	945,000
10559	National Alliance of State and Territorial AIDS Directors	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	375,000
10564	Population Council	NGO	U.S. Agency for International Development	GHP-State	600,000
10599	American International Health Alliance Twinning Center	NGO	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	1,000,000
10601	Addis Ababa University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	680,000
10603	American Society of Clinical	NGO	U.S. Department of Health and	GHP-State	90,000



	Pathology		Human Services/Centers for Disease Control and Prevention		
10604	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	150,000
10663	American Society for Microbiology	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	100,000
11033	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	300,000
11036	International Rescue Committee	NGO	U.S. Department of State/Bureau of Population, Refugees, and Migration	GHP-State	0
11040	United Nations High Commissioner for Refugees	Multi-lateral Agency	U.S. Department of State/Bureau of Population, Refugees, and Migration	GHP-State	353,000
12306	Organization for Social Services for AIDS (OSSA)	NGO	U.S. Department of Health and Human Services/Centers	GHP-State	1,950,000



			for Disease Control and Prevention		
12307	Pathfinder International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12313	NETWORK OF NETWORKS OF ETHIOPIANS LIVING WITH HIV/AIDS (NEP+)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,000,000
12314	Ethiopian Society of Obstetricians and Gynecologists	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12319	Federal Police, Ethiopia	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,729,405
12321	Gondar University	University	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	695,000

			Control and Prevention		
13053	Family Guidance Association of Ethiopia	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,980,415
13158	Federal Ministry of Health, Ethiopia	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,673,880
13254	Tulane University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,750,075
13456	Clinton Health Access Initiative	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,000,000
13521	Population Services International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	0

			Prevention		
13530	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13597	Mayo Clinic	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	75,000
13770	Harari Regional Health Bureau	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,322,998
13794	Oromia Health Bureau, Ethiopia	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	10,929,300
13928	Addis Ababa HIV/AIDS Prevention and Control Office	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	0

			Prevention		
13929	Dire Dawa City Administration Health Bureau	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,533,770
13931	Federal HAPCO	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	736,700
13932	Haramaya University	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	560,000
13933	Ethiopian Medical Association	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	210,000
13934	Addis Ababa Health Bureau	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,427,799

13948	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	150,000
14187	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	600,000
14189	World Vision International	FBO	U.S. Agency for International Development	GHP-State	1,308,420
14194	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	0
14195	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	650,000
14209	JHPIEGO	University	U.S. Agency for International Development	GHP-State	1,100,000
14210	John Snow, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	2,360,000
14211	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	2,734,483
14212	United States Pharmacopeia	Private Contractor	U.S. Agency for International Development	GHP-State	600,000
14215	FHI 360	NGO	U.S. Agency for International Development	GHP-State	555,000
14217	World Food	Multi-lateral	U.S. Agency for	GHP-State	4,877,160

	Program	Agency	International Development		
14228	Population Services International	NGO	U.S. Agency for International Development	GHP-State	9,646,246
14230	World Learning	NGO	U.S. Agency for International Development	GHP-State	3,200,000
14232	Pact, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	8,263,988
14267	Regional Procurement Support Office/Frankfurt	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	0
14309	World Health Organization	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	860,000
14351	National Network of Positive Women Ethiopia	NGO	U.S. Agency for International Development	GHP-State	409,200
14354	Partnership for Supply Chain Management	Private Contractor	U.S. Agency for International Development	GHP-State	19,368,383
16738	Ethiopian Public Health Association	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,526,200
16742	National Defense Forces of Ethiopia	Host Country Government Agency	U.S. Department of Health and Human Services/Centers	GHP-State	2,773,703



			for Disease Control and Prevention		
16749	Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	17,409,161
16750	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	813,600
16751	Ethiopian Public Health Institute	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,751,800
16752	Amhara Regional Health Bureau	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	9,434,100
16779	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	100,000

			Control and Prevention		
16798	FHI 360	NGO	U.S. Department of Defense	GHP-State	300,000
16826	FHI 360	NGO	U.S. Agency for International Development	GHP-State	0
16901	SNNPR	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,959,800
16912	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	1,700,000
16927	TBD	TBD	Redacted	Redacted	Redacted
16930	FHI 360	NGO	U.S. Agency for International Development	GHP-State	250,000
16973	TBD	TBD	Redacted	Redacted	Redacted
16974	TBD	TBD	Redacted	Redacted	Redacted
16975	TBD	TBD	Redacted	Redacted	Redacted
17000	Tigray Regional Health Bureau	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,450,087
17265	John Snow, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	550,000
17271	Ethiopian Society	NGO	U.S. Agency for	GHP-State	200,000

	of Sociologists, Social Workers and Anthropologists		International Development		
17272	Hope for Children	NGO	U.S. Agency for International Development	GHP-State	192,000
17635	KNCV Tuberculosis Foundation	NGO	U.S. Agency for International Development	GHP-State	778,718
17641	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	818,010
17746	Peace Corps Volunteers	Implementing Agency	U.S. Peace Corps	GHP-State	0
17824	TBD	TBD	Redacted	Redacted	Redacted
17825	TBD	TBD	Redacted	Redacted	Redacted
17843	TBD	TBD	Redacted	Redacted	Redacted
17856	TBD	TBD	Redacted	Redacted	Redacted
17908	TBD	TBD	Redacted	Redacted	Redacted
17953	TBD	TBD	Redacted	Redacted	Redacted



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 7515</b>	<b>Mechanism Name: Ethiopian National Defense force</b>
Funding Agency: DOD	Procurement Type: Contract
Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 566,736</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	566,736

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Condom procurement	83,636
--------------------	--------

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 7515</b>
---------------------------



<b>Mechanism Name:</b>	<b>Ethiopian National Defense force</b>		
<b>Prime Partner Name:</b>	<b>U.S. Department of Defense (Defense)</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	39,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMBL	344,100	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMIN	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	83,636	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	1	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	1,500	
VMMC_CIRC_DSD	By Age: 15-19	450	

VMMC_CIRC_DSD	By Age: 20-24	580	
VMMC_CIRC_DSD	By Age: 25-49	470	
VMMC_CIRC_DSD	Sum of age disaggregates	1,500	
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	1,500	
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	1,500	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,050	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,050	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	8,000	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,995	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,505	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	3,500	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	3,500	

### Implementing Mechanism Details



<b>Mechanism ID: 10515</b>	<b>Mechanism Name: Capacity Building Assistance for Global HIV/AIDS Laboratory Guidelines and Standards Development and Enhancing Laboratory Quality Improvement Skills through Quality Systems Approach</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Clinical and Laboratory Standards Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 90,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	90,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	9,000
----------------------------	-------

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	<b>10515</b>
<b>Mechanism Name:</b>	<b>Capacity Building Assistance for Global HIV/AIDS Laboratory</b>



<b>Prime Partner Name:</b>	<b>Guidelines and Standards Development and Enhancing Laboratory Quality Improvement Skills through Quality Systems Approach Clinical and Laboratory Standards Institute</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	90,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 10517</b>	<b>Mechanism Name: TBD-G2G HIV/AIDS Antiretroviral Therapy Programme Implementation support through local universities</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Hawassa University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 515,000</b>	
<b>Applied Pipeline Amount: 20,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	515,000

### Sub Partner Name(s)

(No data provided.)



### Cross-Cutting Budget Attribution(s)

Human Resources for Health	53,500
Condom programming	2,675
Gender: GBV	2,675
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Motor Vehicles: Purchased	45,000

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	10517		
<b>Mechanism Name:</b>	TBD-G2G HIV/AIDS Antiretroviral Therapy Programme Implementation		
<b>Prime Partner Name:</b>	support through local universities Hawassa University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	20,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	80,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	25,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Prevention	MTCT	30,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	320,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	40,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	58	111	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	66	117	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	58		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	14	39	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	56	72	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	58		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	70	111	Redacted

PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,560	1,904	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	2,867	2,004	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	55	82	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	11	35	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	66	117	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	350		Redacted
PP_PREV_TA	Total number of people in the target population	500		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	47	105	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	66		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,496	3,560	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	10	14	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	30	48	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	106	83	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	1,254		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	10	11	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	29	43	Redacted

TX_CURR_DSD	Age/Sex: 5-14 Female	95	86	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	1,962		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	280	3,560	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	10		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	10		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	146		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,254		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	134		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,962		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	280		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	3,216		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	3,496		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	20		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	504	866	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	3	4	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	10	13	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	17	15	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	18	7	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	8	4	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	17	16	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	150	231	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	13	27	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	4	4	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	10	10	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	16	12	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	18	7	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	25	11	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	50	82	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	135	413	Redacted

TX_NEW_DSD	By Age/Sex: 50+ Female	10	10	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	504	866	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	3		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	48		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	188		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	4		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	48		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	220		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	504		Redacted
TX_NEW_DSD	Pregnancy status	14		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	386	379	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	483	446	Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	200	100	Redacted
HRH_PRE	By Graduates: Doctors	200	100	Redacted
HRH_PRE	Sum of Graduates disaggreagtes	200	100	Redacted
FPINT_SITE_DSD	Number of service delivery points	1		Redacted



	supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services			
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	1		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	1		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	1		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	1		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	1		Redacted
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	1		Redacted
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	1		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 10534</b>	<b>Mechanism Name: Improving HIV/AIDS Prevention and Control Activities in the FDRE</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Federal Ministry of Health, Ethiopia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC



<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 10534</b>			
<b>Mechanism Name: Improving HIV/AIDS Prevention and Control Activities in the FDRE</b>			
<b>Prime Partner Name: Federal Ministry of Health, Ethiopia</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 10548</b>	<b>Mechanism Name: TBD-G2G HIV/AIDS Anti-Retroviral Therapy Programme Implementation Support through Local Universities</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Jimma University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 600,000</b>	
<b>Applied Pipeline Amount: 20,000</b>	
Funding Source	Funding Amount
GHP-State	600,000



**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Condom programming	3,100
Gender: GBV	3,100
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	62,000
Motor Vehicles: Purchased	45,000

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	10548		
<b>Mechanism Name:</b>	TBD-G2G HIV/AIDS Anti-Retroviral Therapy Programme Implementation		
<b>Prime Partner Name:</b>	Support through Local Universities Jimma University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	25,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	140,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	25,000	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	320,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	60,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	25	137	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	26	145	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	25		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	10	48	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	15	89	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	25		Redacted
PMTCT_ARV_DS	Sum of New and Current disaggregates	25	137	Redacted

D				
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,176	5,056	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	1,294	5,322	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	14	102	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	12	44	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	26	146	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	350		Redacted
PP_PREV_TA	Total number of people in the target population	500		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	19	130	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	26		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	10	104	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	9	26	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	19	130	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,622	3,593	Redacted



TX_CURR_DSD	Age/Sex: <1 Male	14	19	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	42	66	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	152	113	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	1,224		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	14	16	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	42	58	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	136	117	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	1,998		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	400	3,593	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	14		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	14		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	208		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,224		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	192		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,998		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	400		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	3,222		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	3,622		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	28		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	599	672	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	5	5	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	13	16	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	21	18	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	24	9	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	7	3	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	15	12	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	133	170	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	11	20	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	4	5	Redacted

TX_NEW_DSD	By Age/Sex: 1-4 Female	13	13	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	21	15	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	23	9	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	35	8	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	71	60	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	189	302	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	14	7	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	599	672	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	5		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	63		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	166		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	4		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	61		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	309		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	599		Redacted
TX_NEW_DSD	Pregnancy status	10		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	380	395	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	475	465	Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of	172	172	Redacted

	PEPFAR-supported strengthening efforts, within the reporting period, by select cadre			
HRH_PRE	By Graduates: Doctors	172	172	Redacted
HRH_PRE	Sum of Graduates disaggregates	172	172	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	1		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	1		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	1		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	1		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	1		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	1		Redacted
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	1		Redacted
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	1		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 10557</b>	<b>Mechanism Name: TBD-G2G HIV/AIDS Anti-Retroviral Therapy Program Implementation Support through Local Universities</b>
----------------------------	---



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Mekele University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 945,000</b>	
<b>Applied Pipeline Amount: 20,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	945,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Condom programming	4,825
Human Resources for Health	96,500
Gender: GBV	4,825
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Motor Vehicles: Purchased	90,000
Key Populations: FSW	9,650
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b>	10557		
<b>Mechanism Name:</b>	TBD-G2G HIV/AIDS Anti-Retroviral Therapy Program Implementation		
<b>Prime Partner Name:</b>	Support through Local Universities Mekele University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	20,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	140,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	175,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	30,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	550,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	30,000	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	76	36	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	84	38	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	76		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	10	13	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	66	23	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	76		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	76	36	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,800	798	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	1,900	840	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	78	27	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	6	11	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	84	38	Redacted

PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	350		Redacted
PP_PREV_TA	Total number of people in the target population	500		Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	7,395	3,636	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	7,395	3,636	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	59	34	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	84		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,365	1,570	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	4	6	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	12	20	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	43	35	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	488		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	4	5	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	12	18	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	38	36	Redacted

TX_CURR_DSD	Age/Sex: 15+ Female	764		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	113	1,570	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	4		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	4		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	59		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	488		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	54		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	764		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	113		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,252		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,365		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	8		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	517	492	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	1	2	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	4	5	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	6	5	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	7	3	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	2	1	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	5	3	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	46	53	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	4	5	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	1	1	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	3	4	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	6	5	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	6	3	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	48	62	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	98	135	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	261	203	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	19	2	Redacted

TX_NEW_DSD	Sum of Age/Sex disaggregates	517	492	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	1		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	18		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	57		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	1		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	16		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	426		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	517		Redacted
TX_NEW_DSD	Pregnancy status	10		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	326	150	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	407	176	Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	150	150	Redacted
HRH_PRE	By Graduates: Doctors	150	150	Redacted
HRH_PRE	Sum of Graduates disaggreagtes	150	150	Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 10559</b>	<b>Mechanism Name: Peer-to-Peer Capacity</b>
----------------------------	--



<b>Building of Ministries of Health in Public Sector HIV Program Management</b>	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Alliance of State and Territorial AIDS Directors	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 375,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	375,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	41,400
Food and Nutrition: Policy, Tools, and Service Delivery	4,140

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	<b>10559</b>
<b>Mechanism Name:</b>	<b>Peer-to-Peer Capacity Building of Ministries of Health in Public Sector</b>
<b>Prime Partner Name:</b>	<b>HIV Program Management</b>



National Alliance of State and Territorial AIDS Directors			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	125,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 10564</b>	<b>Mechanism Name: HIV Prevention for Vulnerable Adolescent Girls</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 600,000</b>	
<b>Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount
GHP-State	600,000

### Sub Partner Name(s)



(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	10564		
<b>Mechanism Name:</b>	HIV Prevention for Vulnerable Adolescent Girls		
<b>Prime Partner Name:</b>	Population Council		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	400,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	6,250	6,250
PP_PREV_DSD	Total number of people in the target population	6,250	40,010
PP_PREV_DSD	Age/sex: 10-14 Female	3,000	1,413



PP_PREV_DSD	Age/sex: 15-19 Female	3,250	4,837
PP_PREV_DSD	Sum of Age/Sex disaggregates	6,250	6,250

### Implementing Mechanism Details

<b>Mechanism ID: 10599</b>	<b>Mechanism Name: Twinning Initiative</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: American International Health Alliance Twinning Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,000,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,000,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	200,000
----------------------------	---------

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 10599
<b>Mechanism Name:</b> Twinning Initiative



<b>Prime Partner Name:</b>	<b>American International Health Alliance Twinning Center</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	1,000,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	166	190	Redacted
HRH_PRE	By Graduates: Other	166	151	Redacted
HRH_PRE	Sum of Graduates disaggreagtes	166	190	Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 10601</b>	<b>Mechanism Name: G2G-TBD - Addis Ababa University - Strengthening HIV/AIDS, STI &amp; TB Prevention, Care &amp; Treatment Activities</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Addis Ababa University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 680,000</b>	
<b>Applied Pipeline Amount: 20,000</b>	



Funding Source	Funding Amount
GHP-State	680,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Renovation	43,500
Human Resources for Health	70,000
Gender: GBV	3,500
Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Condom programming	3,500
Motor Vehicles: Purchased	80,000

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	10601		
<b>Mechanism Name:</b>	G2G-TBD - Addis Ababa University - Strengthening HIV/AIDS, STI & TB		
<b>Prime Partner Name:</b>	Prevention, Care & Treatment Activities		
	Addis Ababa University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	35,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and	OHSS	80,000	0

Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	25,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	420,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	90,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	175	180	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	184	190	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	175		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	105	63	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the	70	117	Redacted

	current pregnancy			
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	175		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	175	180	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	870	4,138	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	900	4,356	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	161	133	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	23	57	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	184	190	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	500		Redacted
PP_PREV_TA	Total number of people in the target population	625		Redacted
PP_PREV_TA	Age/sex: 20-24 Male	350		Redacted
PP_PREV_TA	Age/sex: 20-24 Female	150		Redacted
PP_PREV_TA	Sum of Age/Sex disaggregates	500		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	129	171	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	184		Redacted

PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	67	137	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	62	34	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	129	171	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	4,252	3,764	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	19	38	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	56	129	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	201	221	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	1,378		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	18	30	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	55	114	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	180	228	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	2,345		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	529	3,764	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	431	536	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	7	7	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	20	20	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	32	22	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	36	11	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	3	2	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	7	9	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	59	124	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	5	14	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	6	5	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	19	15	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	32	19	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	31	11	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	20	6	Redacted

TX_NEW_DSD	By Age/Sex: 20-24 Female	40	44	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	106	222	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	8	5	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	431	536	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	7		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	95		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	74		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	6		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	88		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	174		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	431		Redacted
TX_NEW_DSD	Pregnancy status	105		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	198	460	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	247	541	Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	310		Redacted
HRH_PRE	By Graduates: Doctors	310		Redacted



HRH_PRE	Sum of Graduates disaggreagtes	310		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	1		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	1		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	1		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	1		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	1		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	1		Redacted
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	1		Redacted
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	1		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 10603</b>	<b>Mechanism Name: Supporting Laboratory Training and Quality Improvement for Diagnosis and Laboratory Monitoring of HIV/AIDS Patients in Resource-Limited Countries (ASCP)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society of Clinical Pathology	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 90,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	90,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	10,000
----------------------------	--------

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	10603		
<b>Mechanism Name:</b>	Supporting Laboratory Training and Quality Improvement for Diagnosis and Laboratory Monitoring of HIV/AIDS Patients in Resource-Limited		
<b>Prime Partner Name:</b>	Countries (ASCP) American Society of Clinical Pathology		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	90,000	0



## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID: 10604</b>	<b>Mechanism Name: Capacity building assistance to support sustainable HIV/AIDS integrated laboratory program development</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 150,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	150,000

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

Human Resources for Health	15,000
----------------------------	--------

## Key Issues

(No data provided.)

## Budget Code Information

Custom

Page 150 of 352

FACTS Info v3.8.17.0

2015-11-25 11:33 EST



<b>Mechanism ID:</b>	<b>10604</b>		
<b>Mechanism Name:</b>	<b>Capacity building assistance to support sustainable HIV/AIDS</b>		
<b>Prime Partner Name:</b>	<b>integrated laboratory program development</b>		
	<b>Association of Public Health Laboratories</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	150,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 10663</b>	<b>Mechanism Name: Capacity building assistance for global HIV/AIDS microbiological Lab program development</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society for Microbiology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 100,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	100,000

### Sub Partner Name(s)

(No data provided.)



### Cross-Cutting Budget Attribution(s)

Human Resources for Health	10,000
----------------------------	--------

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	10663		
<b>Mechanism Name:</b>	Capacity building assistance for global HIV/AIDS microbiological Lab program development		
<b>Prime Partner Name:</b>	American Society for Microbiology		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 11033</b>	<b>Mechanism Name: Strengthening PEPFAR Visibility</b>
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 300,000</b>	



<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	300,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 11033</b>			
<b>Mechanism Name: Strengthening PEPFAR Visibility</b>			
<b>Prime Partner Name: U.S. Department of State</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	300,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 11036</b>	<b>Mechanism Name: Comprehensive prevention and response program to HIV/AIDS in Adi Harush, Shimmelba, MyAyni Refugee camps</b>
----------------------------	---



Funding Agency: State/PRM	Procurement Type: Cooperative Agreement
Prime Partner Name: International Rescue Committee	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	11036		
<b>Mechanism Name:</b>	Comprehensive prevention and response program to HIV/AIDS in Adi		
<b>Prime Partner Name:</b>	Harush, Shimelba, MyAyni Refugee camps		
<b>Prime Partner Name:</b>	International Rescue Committee		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HKID	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	250	
PP_PREV_DSD	Total number of people in the target population	250	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	250	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	250	

### Implementing Mechanism Details

<b>Mechanism ID: 11040</b>	<b>Mechanism Name: HIV in Refugee Camps</b>
Funding Agency: State/PRM	Procurement Type: Grant
Prime Partner Name: United Nations High Commissioner for Refugees	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
---------	------------------

<b>Total All Funding Sources: 353,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	353,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 11040</b>			
<b>Mechanism Name: HIV in Refugee Camps</b>			
<b>Prime Partner Name: United Nations High Commissioner for Refugees</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	153,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	161	28
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	161	28
PMTCT_ARV_DSD	Life-long ART (including Option B+)	161	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	92	6
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on	69	1

	treatment at the beginning of the current pregnancy		
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	161	0
PMTCT_ARV_DSD	Sum of New and Current disaggregates	161	7
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	5,600	28
PMTCT_STAT_DSD	Number of new ANC and L&D clients	5,640	3,168
PMTCT_STAT_DSD	By: Known positives at entry	90	2
PMTCT_STAT_DSD	By: Number of new positives identified	71	26
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	161	28
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	2	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	354	250
VMMC_CIRC_DSD	By Age: 1-9	38	0
VMMC_CIRC_DSD	By Age: 10-14	130	0
VMMC_CIRC_DSD	By Age: 15-19	98	30
VMMC_CIRC_DSD	By Age: 20-24	33	100
VMMC_CIRC_DSD	By Age: 25-49	45	
VMMC_CIRC_DSD	By Age: 50+	10	0
VMMC_CIRC_DSD	Sum of age disaggregates	354	130
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	26,200	
PP_PREV_DSD	Total number of people in the target population	27,000	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on	264	145

	evidence and/or meet the minimum standards required		
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	264	145
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	35,743	15,283
HTC_TST_DSD	By Test Result: Negative	35,512	15,095
HTC_TST_DSD	By Test Result: Positive	231	188
HTC_TST_DSD	Sum of Test Result disaggregates	35,743	15,283
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	7,827	126
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10,020	7,312
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	7,876	126
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	10,020	7,719
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	15,703	252
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	20,040	15,031
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	35,743	15,283
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,912	114
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical	118	88



	assessment (WHO staging) OR CD4 count OR viral load		
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,566	339
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	402	185
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	64	336
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	70	345
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,912	114

### Implementing Mechanism Details

<b>Mechanism ID: 12306</b>	<b>Mechanism Name: Increasing Access of VCT services to hot spot urban-rural setting and improving care and support at the community level in Federal Democratic Republic of Ethiopia under the President's Emergency Plan for AIDS</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Organization for Social Services for AIDS (OSSA)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 1,950,000</b>	
<b>Applied Pipeline Amount: 100,000</b>	



Funding Source	Funding Amount
GHP-State	1,950,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Gender: GBV	10,250
Focus Area:	GBV Prevention
Sub Area:	Implementation
Human Resources for Health	102,500
Food and Nutrition: Policy, Tools, and Service Delivery	20,500

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> <b>Mechanism Name:</b> <b>Prime Partner Name:</b>	<b>12306</b> <b>Increasing Access of VCT services to hot spot urban-rural setting and improving care and support at the community level in Federal Democratic Republic of Ethiopia under the President's Emergency Plan for AIDS Organization for Social Services for AIDS (OSSA)</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	550,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HVCT	1,400,000	0
------------	------	-----------	---

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	41,000	45,007	Redacted
HTC_TST_DSD	By Test Result: Negative	39,073	42,776	Redacted
HTC_TST_DSD	By Test Result: Positive	1,927	1,832	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	41,000	44,608	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	6,150	4,476	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	14,350	15,844	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6,150	5,415	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	14,350	19,272	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	12,300	9,891	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	28,700	35,116	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	41,000	45,007	Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 12307</b>	<b>Mechanism Name: Prevention of Cervical Cancer among HIV positive women in the Federal Democratic Republic of Ethiopia</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Pathfinder International	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	12307		
<b>Mechanism Name:</b>	Prevention of Cervical Cancer among HIV positive women in the Federal Democratic Republic of Ethiopia		
<b>Prime Partner Name:</b>	Pathfinder International		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)



### Implementing Mechanism Details

<b>Mechanism ID: 12313</b>	<b>Mechanism Name: Support for the Greater Involvement of People Living with HIV/AIDS (GIPA) in the Federal Democratic Republic of Ethiopia</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: NETWORK OF NETWORKS OF ETHIOPIANS LIVING WITH HIV/AIDS (NEP+)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,000,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,000,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 12313</b>
----------------------------



<b>Mechanism Name:</b>	<b>Support for the Greater Involvement of People Living with HIV/AIDS</b>		
<b>Prime Partner Name:</b>	<b>(GIPA) in the Federal Democratic Republic of Ethiopia</b>		
	<b>NETWORK OF NETWORKS OF ETHIOPIANS LIVING WITH HIV/AIDS (NEP+)</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	4,000,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 12314</b>	<b>Mechanism Name: Expansion and Strengthening of the PMTCT Services in the Private Health Facilities in Ethiopia</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ethiopian Society of Obstetricians and Gynecologists	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	12314		
<b>Mechanism Name:</b>	Expansion and Strengthening of the PMTCT Services in the Private Health Facilities in Ethiopia		
<b>Prime Partner Name:</b>	Ethiopian Society of Obstetricians and Gynecologists		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,032		Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,094		Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	1,032		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	459		Redacted



PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	573		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	1,032		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	1,032		Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	40,521		Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	45,024		Redacted
PMTCT_STAT_TA	By: Known positives at entry	656		Redacted
PMTCT_STAT_TA	By: Number of new positives identified	438		Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	1,094		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	766		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	1,094		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	416		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	350		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	766		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	68		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 12319</b>	<b>Mechanism Name: Integrated HIV Prevention Program for Federal Police Force of Ethiopia</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Federal Police, Ethiopia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 1,729,405</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,729,405

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	12319		
<b>Mechanism Name:</b>	Integrated HIV Prevention Program for Federal Police Force of Ethiopia		
<b>Prime Partner Name:</b>	Federal Police, Ethiopia		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	90,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	182,383	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	20,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	47,300	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	130,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	560,353	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	25,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	569,369	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	25,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	54	54	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	54	59	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	54		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	14	19	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	40	35	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	54		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	54	54	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,028	1,028	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	1,068	1,082	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	30	41	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	24	18	Redacted

PMTCT_STAT_DS D	Sum of Positives Status disaggregates	54	59	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	26,890	31,794	Redacted
PP_PREV_DSD	Total number of people in the target population	40,000		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	13,310	15,110	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	9,910	13,964	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	970		Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	1,470	1,470	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	1,100	1,200	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	130		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	26,890	31,794	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,500		Redacted
PP_PREV_TA	Total number of people in the target population	3,000		Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	20,000	15,000	Redacted
HTC_TST_TA	By Test Result: Negative	19,740		Redacted
HTC_TST_TA	By Test Result: Positive	260		Redacted
HTC_TST_TA	Sum of Test Result disaggregates	20,000		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	200	1,479	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	17,800	4,304	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ	200	1,260	Redacted

	PERMISSION ONLY: <15 Female			
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,800	7,957	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	400	2,739	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	19,600	12,261	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	20,000	15,000	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,122	3,033	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	74		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,168		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	68		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	812		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	2,122		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	142	401	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	5		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	80		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	5		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	52		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	142		Redacted

CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	142		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	400	82	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	400		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	38	53	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	54		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	34	42	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	20	13	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	54	55	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,810	2,725	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	5	7	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	15	23	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	54	39	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	1,708		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	5	5	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	15	20	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	48	41	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	960		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	142	2,725	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	5		Redacted

TX_CURR_DSD	Aggregated Age/Sex: <1 Female	5		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	74		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,708		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	68		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	960		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	142		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	2,668		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,810		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	10		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	331	390	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	1	2	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	2	5	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	2	5	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	0	3	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	10	2	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	21	8	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	182	105	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	15	12	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	1	2	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	2	4	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	2	5	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	0	3	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	11	4	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	21	38	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	57	188	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	4	4	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	331	390	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	1		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15	5		Redacted

	Male			
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	228		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	1		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	5		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	93		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	331		Redacted
TX_NEW_DSD	Pregnancy status	14		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	250	273	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	321	276	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	1	1	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	1		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	1		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	1		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	3	3	Redacted

LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	3		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	3		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	3		Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	120		Redacted
HRH_PRE	By Graduates: Nurses	40		Redacted
HRH_PRE	By Graduates: Other	80		Redacted
HRH_PRE	Sum of Graduates disaggreagtes	120		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	3		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	3		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	3		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	3		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	3		Redacted
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	3		Redacted



FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	3		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	1,910	2,973	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,122	3,033	Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 12321</b>	<b>Mechanism Name: HIV/AIDS Antiretroviral therapy implementation support through local universities</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Gondar University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 695,000</b>	
<b>Applied Pipeline Amount: 25,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	695,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	45,000
---------------------------	--------



Condom programming	3,635
Gender: GBV	3,636
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	72,000
Education	16,775

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	12321		
<b>Mechanism Name:</b>	HIV/AIDS Antiretroviral therapy implementation support through local universities		
<b>Prime Partner Name:</b>	Gondar University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	35,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	135,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	25,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	30,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Treatment	HTXS	370,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	100,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	300	138	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	340	146	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	300		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	170	48	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	130	90	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	300		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	300	138	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	8,130	4,571	Redacted

PMTCT_STAT_DS D	Number of new ANC and L&D clients	9,146	4,812	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	180	102	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	160	44	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	340	146	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,500		Redacted
PP_PREV_TA	Total number of people in the target population	3,125		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	238	131	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	340		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	130	105	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	108	26	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	238	131	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	6,570	6,334	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	31	41	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	93	138	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	331	236	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	2,223		Redacted

TX_CURR_DSD	Age/Sex: <1 Female	30	33	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	90	122	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	296	244	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	3,476		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	871	6,334	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	31		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	30		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	455		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,223		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	416		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	3,476		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	871		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	5,699		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	6,570		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	61		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,030	924	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	12	11	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	35	34	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	56	37	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	63	19	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	10	4	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	21	15	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	184	215	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	16	25	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	11	9	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	34	26	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	56	32	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	62	19	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	53	10	Redacted

TX_NEW_DSD	By Age/Sex: 20-24 Female	108	76	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	288	383	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	21	9	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,030	924	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	12		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	166		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	231		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	11		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	163		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	470		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,030		Redacted
TX_NEW_DSD	Pregnancy status	170		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	560	725	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	700	853	Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	196	175	Redacted
HRH_PRE	By Graduates: Doctors	196		Redacted



HRH_PRE	Sum of Graduates disaggreagtes	196		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	1		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	1		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	1		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	1		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	1		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	1		Redacted
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	1		Redacted
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	1		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13053</b>	<b>Mechanism Name: Strengthening Integration of PMTCT/STIs/HTC with Reproductive Health Services at Family Guidance Association's of Ethiopia Clinics and Youth Centers</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Family Guidance Association of Ethiopia	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 1,980,415</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,980,415

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Renovation	42,000
------------	--------

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	13053		
<b>Mechanism Name:</b>	Strengthening Integration of PMTCT/STIs/HTC with Reproductive Health Services at Family Guidance Association's of Ethiopia Clinics and Youth		
<b>Prime Partner Name:</b>	Centers Family Guidance Association of Ethiopia		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	600,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	800,415	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	130,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	450,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	450	188	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	450	199	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	450		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	230	67	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	220	121	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	450		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	450	188	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were	24,850	17,897	Redacted

	tested for HIV and received their results)			
PMTCT_STAT_DS D	Number of new ANC and L&D clients	24,850	18,839	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	230	140	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	220	60	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	450	200	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	11,480		Redacted
PP_PREV_TA	Total number of people in the target population	14,350		Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	23,000	23,939	Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	23,000	23,939	Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	90,000	100,000	Redacted
HTC_TST_DSD	By Test Result: Negative	85,500	96,893	Redacted
HTC_TST_DSD	By Test Result: Positive	4,500	3,107	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	90,000	100,000	Redacted

HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,800	538	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	20,700	18,798	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,700	458	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	64,800	80,206	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	4,500	996	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	85,500	99,004	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	90,000	100,000	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	315	178	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	450		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	165	143	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	150	35	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	315	178	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	512	1,372	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	512		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	512		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	512		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	512		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	350	1,084	Redacted

TX_NEW_DSD	By Age/Sex: 15-19 Female	105	16	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	70	112	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	175	581	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	350	1,084	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	350		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	350		Redacted
TX_NEW_DSD	Pregnancy status	230		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	20		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	20		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	20		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	20		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	20		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	20		Redacted
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	20		Redacted
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	20		Redacted



### Implementing Mechanism Details

<b>Mechanism ID: 13158</b>	<b>Mechanism Name: Supporting the National Blood Transfusion services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Federal Ministry of Health, Ethiopia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 1,673,880</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,673,880

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	13158		
<b>Mechanism Name:</b>	Supporting the National Blood Transfusion services		
<b>Prime Partner Name:</b>	Federal Ministry of Health, Ethiopia		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HMBL	1,673,880	0
------------	------	-----------	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13254</b>	<b>Mechanism Name: Technical Assistance in support of HIV prevention, care, and treatment program and other infectious diseases</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Tulane University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,750,075</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,750,075

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b>	13254		
<b>Mechanism Name:</b>	Technical Assistance in support of HIV prevention, care, and treatment program and other infectious diseases		
<b>Prime Partner Name:</b>	Tulane University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	2,150,075	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	600,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	762	853	Redacted
HRH_PRE	By Graduates: Doctors	48	74	Redacted
HRH_PRE	By Graduates: Other	714	779	Redacted
HRH_PRE	Sum of Graduates disaggregates	762	853	Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13456</b>	<b>Mechanism Name: Ethiopian Health Management Initiative (EHMI)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Clinton Health Access Initiative	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,000,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,000,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	13456		
<b>Mechanism Name:</b>	Ethiopian Health Management Initiative (EHMI)		
<b>Prime Partner Name:</b>	Clinton Health Access Initiative		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	1,000,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	44	55	Redacted
HRH_PRE	By Graduates: Other	44		Redacted
HRH_PRE	Sum of Graduates disaggreagtes	44		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13521</b>	<b>Mechanism Name: Community outreach and social mobilization for prevention</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)



(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 13521			
<b>Mechanism Name:</b> Community outreach and social mobilization for prevention			
<b>Prime Partner Name:</b> Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 13530	<b>Mechanism Name:</b> Technical assistance to build host government capacity
Funding Agency: HHS/CDC	Procurement Type: USG Core
Prime Partner Name: U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 0	
<b>Applied Pipeline Amount:</b> 64,700	
Funding Source	Funding Amount



GHP-State	0
-----------	---

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13530		
<b>Mechanism Name:</b>	Technical assistance to build host government capacity		
<b>Prime Partner Name:</b>	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0



## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID: 13597</b>	<b>Mechanism Name: Continued Education Health Workers</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Mayo Clinic	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 75,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	75,000

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

Human Resources for Health	75,000
----------------------------	--------

## Key Issues

(No data provided.)

## Budget Code Information



<b>Mechanism ID:</b> 13597			
<b>Mechanism Name:</b> Continued Education Health Workers			
<b>Prime Partner Name:</b> Mayo Clinic			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	75,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 13770	<b>Mechanism Name:</b> Support to GOE Regional Health Bureau in Harari
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Harari Regional Health Bureau	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources:</b> 1,322,998	
<b>Applied Pipeline Amount:</b> 25,000	
Funding Source	Funding Amount
GHP-State	1,322,998

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Condom programming	6,739
--------------------	-------



Key Populations: FSW	13,479
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Water	6,739
Gender: GBV	6,739
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Education	13,479
Human Resources for Health	134,799
Food and Nutrition: Policy, Tools, and Service Delivery	13,479
Renovation	52,500
Motor Vehicles: Purchased	25,000

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	13770		
<b>Mechanism Name:</b>	Support to GOE Regional Health Bureau in Harari		
<b>Prime Partner Name:</b>	Harari Regional Health Bureau		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	90,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	100,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	20,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	40,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	24,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	43,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	15,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	45,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	30,571	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	60,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	820,427	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDTX	35,000	0
-----------	------	--------	---

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	192	69	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	239	73	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	171		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	48	24	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	123	45	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	171		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	171	69	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	10,771	4,252	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	10,990	4,476	Redacted

PMTCT_STAT_DS D	By: Known positives at entry	118	52	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	121	22	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	239	74	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,000		Redacted
PP_PREV_TA	Total number of people in the target population	1,250		Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	70,000	53,152	Redacted
HTC_TST_TA	By Test Result: Negative	69,090	52,332	Redacted
HTC_TST_TA	By Test Result: Positive	910	820	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	70,000	53,152	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,900		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	30,100		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,600		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	29,400		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	10,500		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	59,500		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	70,000		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting	4,432	4,300	Redacted

	period: clinical assessment (WHO staging) OR CD4 count OR viral load			
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	63		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,768		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	57		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,544		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	4,432		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	816	426	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	27		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	254		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	27		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	508		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	816		Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	816		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	800	122	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	840	367	Redacted
TB_ART_DSD	The number of registered new and	112	83	Redacted

	relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period			
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	112	83	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	168	66	Redacted
PMTCT_EID_DSD	Number of HIV-positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	239		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	88	53	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	80	13	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	168	66	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,275	1,871	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	4	5	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	12	17	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	44	29	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	713		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	4	3	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	12	14	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	39	32	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	1,447		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	115	1,871	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	4		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	4		Redacted

TX_CURR_DSD	Aggregated Age/Sex: <15 Male	60		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	713		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	55		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,447		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	115		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	2,160		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,275		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	8		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	426	272	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	1	1	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	3	7	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	5	5	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	6	2	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	5	1	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	12	4	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	98	70	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	8	9	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	1	1	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	3	4	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	5	5	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	5	2	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	31	5	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	63	32	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	168	121	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	12	3	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	426	272	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	1		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	15		Redacted

TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	123		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	1		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	14		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	274		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	426		Redacted
TX_NEW_DSD	Pregnancy status	48		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	317	255	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	396	300	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	1	6	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	1		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	1		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	1		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	12	84	Redacted
LAB_CAP_DSD	By site support type: Direct Service	12		Redacted



	Delivery (DSD)			
LAB_CAP_DSD	Sum of Site Support Type disaggregates	12		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	12		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	12		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	12		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	12		Redacted
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	12		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	3,978	4,450	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	4,432	4,300	Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13794</b>	<b>Mechanism Name: Oromia Regional Health Bureau HIV/AIDS program</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Oromia Health Bureau, Ethiopia	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 10,929,300</b>	
<b>Applied Pipeline Amount: 130,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	10,929,300

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Condom programming	54,937
Gender: GBV	54,937
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Key Populations: FSW	109,875
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Food and Nutrition: Policy, Tools, and Service Delivery	109,875
Water	54,937
Education	109,875
Human Resources for Health	1,098,754
Renovation	2,236,231
Motor Vehicles: Purchased	480,676

## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 13794			
<b>Mechanism Name:</b> Oromia Regional Health Bureau HIV/AIDS program			
<b>Prime Partner Name:</b> Oromia Health Bureau, Ethiopia			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	370,700	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	110,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	93,600	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	190,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	175,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	900,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	6,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	990,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	7,502	4,240	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	8,435	4,411	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	7,502		Redacted

PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	4,501	1,491	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	3,001	2,749	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	7,502	0	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	7,502	4,240	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	401,717	458,728	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	519,293	482,873	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	5,061	3,095	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	3,374	1,323	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	8,435	4,418	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	15,850		Redacted
PP_PREV_TA	Total number of people in the target population	19,812		Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,000,000	1,381,075	Redacted
HTC_TST_TA	By Test Result: Negative	987,000	1,359,498	Redacted
HTC_TST_TA	By Test Result: Positive	13,000	21,577	Redacted

HTC_TST_TA	Sum of Test Result disaggregates	1,000,000	1,381,075	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	70,000	135,464	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	430,000	392,218	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	80,000	114,908	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	420,000	738,485	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	150,000	250,372	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	850,000	1,130,703	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	1,000,000	1,381,075	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	122,144	117,102	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,181		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	45,928		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,938		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	66,097		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	122,144		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	31,803	20,289	Redacted

CARE_NEW_DSD	Aggregated Age/sex: <15 Male	685		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	11,673		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	714	47	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	18,731		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	31,803	47	Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	31,803	47	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	14,643	2,574	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	15,834	8,288	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,717	2,822	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,717	2,822	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	5,905	3,967	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	8,435		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,000	3,172	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12	2,905	795	Redacted

	months of age			
PMTCT_EID_DSD	Sum of Infant Age disaggregates	5,905	3,967	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	102,194	104,333	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	350	522	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	1,097	1,778	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	3,667	3,036	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	35,039		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	349	419	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	1,000	1,573	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	3,524	3,154	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	57,168		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	9,987	104,333	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	350		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	349		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	5,114		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	35,039		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	4,873		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	57,168		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	9,987		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	92,207		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	102,194		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	699		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	21,441	18,151	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	109	118	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	327	392	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	566	457	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	585	212	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	278	75	Redacted

TX_NEW_DSD	By Age/Sex: 20-24 Male	583	300	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	5,144	4,626	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	437	529	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	100	99	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	300	316	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	500	410	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	550	212	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	1,353	198	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	2,745	1,632	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	7,336	8,389	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	528	186	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	21,441	18,151	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	109		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,587		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	6,442		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	100		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,450		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	11,962		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	21,441		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	14,722	11,622	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	18,403	13,831	Redacted

LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	4	12	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	4		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	4		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	4		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	451	602	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	451		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	451		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	451		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	302		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	109,619	114,092	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	122,144	117,102	Redacted

### Implementing Mechanism Details



<b>Mechanism ID: 13928</b>	<b>Mechanism Name: Addis Ababa Regional HIV/AIDS Prevention and Control Office</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Addis Ababa HIV/AIDS Prevention and Control Office	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 13928</b>			
<b>Mechanism Name: Addis Ababa Regional HIV/AIDS Prevention and Control Office</b>			
<b>Prime Partner Name: Addis Ababa HIV/AIDS Prevention and Control Office</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and	OHSS	0	0



Systems			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	10,000		Redacted
HTC_TST_DSD	By Test Result: Negative	9,510		Redacted
HTC_TST_DSD	By Test Result: Positive	490		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	10,000		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	700		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,300		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	800		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,200		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,500		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	8,500		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	10,000		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13929</b>	<b>Mechanism Name: Dire-Dawa Health Bureau HIV/AIDS program</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Dire Dawa City Administration Health Bureau	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 1,533,770</b>	
<b>Applied Pipeline Amount: 25,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,533,770

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Condom programming	7,793
Key Populations: FSW	15,587
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Water	7,793
Food and Nutrition: Policy, Tools, and Service Delivery	15,587
Gender: GBV	7,793
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation



Sub Area:	Capacity building
Human Resources for Health	155,877
Education	15,587
Renovation	115,000

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	13929		
<b>Mechanism Name:</b>	Dire-Dawa Health Bureau HIV/AIDS program		
<b>Prime Partner Name:</b>	Dire Dawa City Administration Health Bureau		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	110,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	120,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	25,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	40,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	29,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Governance and Systems	OHSS	43,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMBL	14,800	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	42,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	25,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	61,372	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	955,598	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	68,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	386	311	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	482	326	Redacted

PMTCT_ARV_DS D	Life-long ART (including Option B+)	386		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	137	109	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	249	202	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	386		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	386	311	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	13,765	15,543	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	20,007	16,361	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	289	225	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	193	101	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	482	326	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,750		Redacted
PP_PREV_TA	Total number of people in the target population	2,187		Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	70,000	61,695	Redacted
HTC_TST_TA	By Test Result: Negative	69,090	60,726	Redacted

HTC_TST_TA	By Test Result: Positive	910	969	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	70,000	61,695	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,900	6,057	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	30,100	17,592	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,600	5,159	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	29,400	32,887	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	10,500	11,216	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	59,500	50,479	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	70,000	61,695	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	7,950	7,500	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	248		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,066		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	224		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,412		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	7,950		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO	1,775	710	Redacted

	staging) OR CD4 count OR viral load			
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	38		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	651		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	40		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,046		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	1,775		Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	1,775		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	1,031	201	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	1,031	571	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	78	126	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	78	126	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	338	294	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	482		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	7,106	6,857	Redacted

TX_CURR_DSD	Age/Sex: <1 Male	17	24	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	50	82	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	177	138	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	2,324		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	16	19	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	48	72	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	158	144	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	4,316		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	466	6,857	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	17		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	16		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	244		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,324		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	222		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	4,316		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	466		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	6,640		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	7,106		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	33		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,197	844	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	4	6	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	12	24	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	19	22	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	23	9	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	17	3	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	36	15	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	320	214	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	27	26	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	4	5	Redacted

TX_NEW_DSD	By Age/Sex: 1-4 Female	12	15	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	19	19	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	20	9	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	77	9	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	157	77	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	420	382	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	30	9	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,197	844	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	4		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	58		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	400		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	4		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	55		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	684		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,197		Redacted
TX_NEW_DSD	Pregnancy status	137		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	624	806	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	800	948	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or	1	6	Redacted



	international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation			
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	1		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	1		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	1		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	21	26	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	21		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	21		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	21		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	12	12	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	7,141	7,352	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	7,950	7,500	Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13931</b>	<b>Mechanism Name: Federal HAPCO Support</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Federal HAPCO	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 736,700</b>	
<b>Applied Pipeline Amount: 45,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	736,700

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	78,170
Condom programming	3,908

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	13931		
<b>Mechanism Name:</b>	Federal HAPCO Support		
<b>Prime Partner Name:</b>	Federal HAPCO		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	121,700	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	OHSS	90,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	225,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	300,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13932</b>	<b>Mechanism Name: HIV/AIDS Antiretroviral therapy program implementation support through local universities</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Haramaya University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 560,000</b>	
<b>Applied Pipeline Amount: 25,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	560,000

### Sub Partner Name(s)

(No data provided.)



### Cross-Cutting Budget Attribution(s)

Condom programming	2,925
Gender: GBV	2,925
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	58,500
Education	5,850
Renovation	16,775

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	13932		
<b>Mechanism Name:</b>	HIV/AIDS Antiretroviral therapy program implementation support through local universities		
<b>Prime Partner Name:</b>	Haramaya University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	20,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	75,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	25,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Prevention	MTCT	30,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	370,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	40,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	102	67	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	110	70	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	102		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	12	23	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	90	44	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	102		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	102	67	Redacted

PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,305	1,835	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	3,701	1,932	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	100	49	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	10	21	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	110	70	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	350		Redacted
PP_PREV_TA	Total number of people in the target population	500		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	77	63	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	110		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	40	50	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	37	13	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	77	63	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,131	1,787	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	9	12	Redacted

TX_CURR_DSD	Age/Sex: 1-4 Male	26	41	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	92	70	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	623		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	8	10	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	25	36	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	82	72	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	1,266		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	242	1,787	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	9		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	8		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	127		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	623		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	115		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,266		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	242		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,889		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,131		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	17		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	277	283	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	2	4	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	6	13	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	10	14	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	11	7	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	2	1	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	5	4	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	42	62	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	4	7	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	2	4	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	6	10	Redacted

TX_NEW_DSD	By Age/Sex: 5-9 Female	9	12	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	10	7	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	19	3	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	39	22	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	103	110	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	7	3	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	277	283	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	2		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	29		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	53		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	2		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	27		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	168		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	277		Redacted
TX_NEW_DSD	Pregnancy status	12		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	177	176	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	221	208	Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening	90	164	Redacted



	efforts, within the reporting period, by select cadre			
HRH_PRE	By Graduates: Doctors	90		Redacted
HRH_PRE	Sum of Graduates disaggreagtes	90		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	1		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	1		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	1		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	1		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	1		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	1		Redacted
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	1		Redacted
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	1		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13933</b>	<b>Mechanism Name: Strengthening Human Resources for Health through increased capacity of the Ethiopian Medical Association</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Ethiopian Medical Association	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 210,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	210,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	21,000
----------------------------	--------

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13933		
<b>Mechanism Name:</b>	Strengthening Human Resources for Health through increased capacity of the Ethiopian Medical Association		
<b>Prime Partner Name:</b>	Ethiopian Medical Association		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	70,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	140,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 13934</b>	<b>Mechanism Name: Strengthening local ownership for sustainable provision of HIV/AIDS services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Addis Ababa Health Bureau	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 6,427,799</b>	
<b>Applied Pipeline Amount: 60,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	6,427,799

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Renovation	347,334
Human Resources for Health	325,000
Gender: GBV	32,500



Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Key Populations: FSW	65,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Food and Nutrition: Policy, Tools, and Service Delivery	65,000
Water	32,500
Condom programming	32,500
Education	65,000
Motor Vehicles: Purchased	300,000

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	13934		
<b>Mechanism Name:</b>	Strengthening local ownership for sustainable provision of HIV/AIDS services		
<b>Prime Partner Name:</b>	Addis Ababa Health Bureau		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	660,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HVTB	150,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	90,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	134,900	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	40,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMBL	37,540	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	125,034	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	90,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	550,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	3,950,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	500,325	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	2,070	3,674	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,180	3,929	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	2,070		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,062	1,287	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,008	2,387	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	2,070		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	2,070	3,674	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their	49,863	84,056	Redacted

	results)			
PMTCT_STAT_DS D	Number of new ANC and L&D clients	54,850	88,483	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	1,330	2,772	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	850	1,189	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	2,180	3,961	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,150		Redacted
PP_PREV_TA	Total number of people in the target population	3,937		Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	400,000	479,935	Redacted
HTC_TST_TA	By Test Result: Negative	386,400	462,451	Redacted
HTC_TST_TA	By Test Result: Positive	13,600	17,484	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	400,000	479,935	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	28,000	45,846	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	172,000	134,496	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	32,000	39,032	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	168,000	260,561	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	60,000	84,878	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	340,000	395,057	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	400,000	479,935	Redacted

CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	84,361	78,804	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,050		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	32,977		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,878		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	47,456		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	84,361		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	7,926	10,519	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	171		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	2,909		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	178		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	4,668		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	7,926		Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	7,926		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	8,000	1,957	Redacted
FN_THER_DSD	Number of PLHIV who were	9,264	6,159	Redacted

	nutritionally assessed and found to be clinically undernourished.			
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	652		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	652		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,526	3,394	Redacted
PMTCT_EID_DSD	Number of HIV-positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	2,180		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	88,764	69,541	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	136	202	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	414	695	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	1,471	1,183	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	33,108		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	135	165	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	400	615	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	1,316	1,228	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	51,784		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	3,872	69,541	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	4		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving	60		Redacted

	antiretroviral therapy (ART) [CURRENT]			
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	136		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	135		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,021		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	33,108		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,851		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	51,784		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,872		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	84,892		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	88,764		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	271		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	14,137	9,897	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	35	35	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	111	111	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	171	118	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	192	60	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	204	50	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	428	188	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	3,775	2,717	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	320	313	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	35	28	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	100	81	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	171	104	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	190	60	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	951	123	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,929	957	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	5,154	4,839	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	371	113	Redacted

TX_NEW_DSD	Sum of Age/Sex disaggregates	14,137	9,897	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	35		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	509		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	4,727		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	35		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	496		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	8,405		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	14,137		Redacted
TX_NEW_DSD	Pregnancy status	2,180		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,070	8,548	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	9,044	10,054	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	3	12	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	3		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	3		Redacted

LAB_ACC_TA	Sum of Support Type disaggregates	3		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	65	130	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	65		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	65		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	65		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	67		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	67		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	67		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	67		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	67		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	67		Redacted
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	67		Redacted
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	67		Redacted



TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	75,794		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	84,361	78,804	Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 13948</b>	<b>Mechanism Name: Nursing Capacity Building Program</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 150,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	150,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	30,000
----------------------------	--------



### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 13948			
<b>Mechanism Name:</b> Nursing Capacity Building Program			
<b>Prime Partner Name:</b> Columbia University Mailman School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	150,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 14187	<b>Mechanism Name:</b> Help Ethiopian Address the Low TB (HEAL TB)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 600,000	
<b>Applied Pipeline Amount:</b> 0	
Funding Source	Funding Amount
GHP-State	600,000



**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 14187			
<b>Mechanism Name:</b> Help Ethiopian Address the Low TB (HEAL TB)			
<b>Prime Partner Name:</b> Management Sciences for Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	600,000	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2015	2016
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status whoare on ART during TB treatment during the reporting period	280	255
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	280	255

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 14189	<b>Mechanism Name:</b> Preventive Care Package
----------------------------	--



	(PCP)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: World Vision International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,308,420</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,308,420

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	14189		
<b>Mechanism Name:</b>	Preventive Care Package (PCP)		
<b>Prime Partner Name:</b>	World Vision International		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	1,213,420	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Care	PDCS	95,000	0
------	------	--------	---

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	57,594	
CARE_CURR_DSD	Age/sex: <1 Male	15	
CARE_CURR_DSD	Age/sex: 1-4 Male	15	
CARE_CURR_DSD	Age/sex: 5-9 Male	234	
CARE_CURR_DSD	Age/sex: 10-14 Male	367	
CARE_CURR_DSD	Age/sex: 15-19 Male	245	
CARE_CURR_DSD	Age/sex: 20-24 Male	249	
CARE_CURR_DSD	Age/sex: 25-49 Male	241	
CARE_CURR_DSD	Age/sex: 50+ Male	220	
CARE_CURR_DSD	Age/sex: <1 Female	1,456	
CARE_CURR_DSD	Age/sex: 1-4 Female	1,511	
CARE_CURR_DSD	Age/sex: 5-9 Female	2,998	
CARE_CURR_DSD	Age/sex: 10-14 Female	3,847	
CARE_CURR_DSD	Age/sex: 15-19 Female	15,342	
CARE_CURR_DSD	Age/sex: 20-24 Female	27,866	
CARE_CURR_DSD	Age/sex: 25-49 Female	1,002	
CARE_CURR_DSD	Age/sex: 50+ Female	1,986	
CARE_CURR_DSD	Sun of Age/Sex disaggregates	57,594	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count	57,594	



	OR viral load		
--	---------------	--	--

**Implementing Mechanism Details**

<b>Mechanism ID: 14194</b>	<b>Mechanism Name: Private Health Sector Program</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	14194
<b>Mechanism Name:</b>	Private Health Sector Program
<b>Prime Partner Name:</b>	Abt Associates



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 14195</b>	<b>Mechanism Name: Leadership Management and Governance</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 650,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	650,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues



(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	14195		
<b>Mechanism Name:</b>	Leadership Management and Governance		
<b>Prime Partner Name:</b>	Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	650,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	240	1,200
HRH_PRE	By Graduates: Other	240	480
HRH_PRE	Sum of Graduates disaggreagtes	240	1,200

### Implementing Mechanism Details

<b>Mechanism ID: 14209</b>	<b>Mechanism Name: Strengthening Human Resources for Health</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,100,000</b>	
---	--



<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,100,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	14209		
<b>Mechanism Name:</b>	Strengthening Human Resources for Health		
<b>Prime Partner Name:</b>	JHPIEGO		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	1,100,000	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2015	2016
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select	3,589	7,894



	cadre		
HRH_PRE	By Graduates: Midwives	2,709	2,549
HRH_PRE	By Graduates: Other	880	5,345
HRH_PRE	Sum of Graduates disaggreagtes	3,589	7,894

### Implementing Mechanism Details

<b>Mechanism ID: 14210</b>	<b>Mechanism Name: Strengthening Ethiopia's Urban Health Program</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,360,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,360,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information



<b>Mechanism ID:</b> 14210			
<b>Mechanism Name:</b> Strengthening Ethiopia's Urban Health Program			
<b>Prime Partner Name:</b> John Snow, Inc.			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	220,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	740,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	32,397	
PP_PREV_DSD	Total number of people in the target population	39,000	
PP_PREV_DSD	Age/sex: 25-49 Male	8,100	
PP_PREV_DSD	Age/sex: 25-49 Female	24,297	
PP_PREV_DSD	Sum of Age/Sex disaggregates	32,397	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	26,843	
HTC_TST_DSD	By Test Result: Negative	26,575	



HTC_TST_DSD	By Test Result: Positive	268	
HTC_TST_DSD	Sum of Test Result disaggregates	26,843	
HTC_TST_DSD	Age/sex: 15-19 Male	1,138	
HTC_TST_DSD	Age/sex: 20-24 Male	2,350	
HTC_TST_DSD	Age/sex: 25-49 Male	3,021	
HTC_TST_DSD	Age/sex: 50+ Male	202	
HTC_TST_DSD	Age/sex: 15-19 Female	3,424	
HTC_TST_DSD	Age/sex: 20-24 Female	7,047	
HTC_TST_DSD	Age/sex: 25-49 Female	9,061	
HTC_TST_DSD	Age/sex: 50+ Female	600	
HTC_TST_DSD	Sum of Age/Sex disaggregates	26,843	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	6,711	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	20,132	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	26,843	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	26,843	

### Implementing Mechanism Details

<b>Mechanism ID: 14211</b>	<b>Mechanism Name: Systems for Improved Access to Pharmaceuticals and Services</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,734,483</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,734,483



**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 14211			
<b>Mechanism Name:</b> Systems for Improved Access to Pharmaceuticals and Services			
<b>Prime Partner Name:</b> Management Sciences for Health			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	325,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	2,300,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	109,483	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 14212	<b>Mechanism Name:</b> Promoting the Quality of Medicines Program
----------------------------	---



Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: United States Pharmacopeia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 600,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	600,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 14212			
<b>Mechanism Name:</b> Promoting the Quality of Medicines Program			
<b>Prime Partner Name:</b> United States Pharmacopeia			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	600,000	0



## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID: 14215</b>	<b>Mechanism Name: Food and Nutrition Technical Assistance III</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 555,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	555,000

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b>	<b>14215</b>
----------------------	--------------



<b>Mechanism Name:</b> Food and Nutrition Technical Assistance III			
<b>Prime Partner Name:</b> FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	55,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	300,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 14217	<b>Mechanism Name:</b> Urban HIV/AIDS Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: World Food Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 4,877,160	
<b>Applied Pipeline Amount:</b> 0	
Funding Source	Funding Amount
GHP-State	4,877,160



**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 14217			
<b>Mechanism Name:</b> Urban HIV/AIDS Project			
<b>Prime Partner Name:</b> World Food Program			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	3,666,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	75,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	336,160	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	800,000	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2015	2016
------------------	-------	------	------

OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	343	
OVC_ACC_DSD	Sex: Male	180	
OVC_ACC_DSD	Sex: Female	163	
OVC_ACC_DSD	Sum of Sex disaggregates	343	
OVC_ACC_DSD	Age: <1	0	
OVC_ACC_DSD	Age: 1-4	71	
OVC_ACC_DSD	Age: 5-9	127	
OVC_ACC_DSD	Age: 10-14	106	
OVC_ACC_DSD	Age: 15-17	39	
OVC_ACC_DSD	Sum of Age disaggregates	343	
OVC_ACC_TA	Sum of Sex disaggregates	343	
OVC_ACC_TA	Sum of Age disaggregates	343	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	12,500	
OVC_SERV_DSD	Sex: Male	6,324	
OVC_SERV_DSD	Sex: Female	6,176	
OVC_SERV_DSD	Sum of Sex disaggregates	12,500	
OVC_SERV_DSD	Age: <1	96	
OVC_SERV_DSD	Age: 1-4	1,685	
OVC_SERV_DSD	Age: 5-9	4,282	
OVC_SERV_DSD	Age: 10-14	5,064	
OVC_SERV_DSD	Age: 15-17	1,373	
OVC_SERV_DSD	Age: 18+	0	
OVC_SERV_DSD	Sum of Age disaggregates	12,500	
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	3,537	551
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	3,537	551



FN_THER_DSD	Age: 1-4	71	
FN_THER_DSD	Age: 5-14	233	
FN_THER_DSD	Age: 15-17	39	
FN_THER_DSD	Age: 18+	3,194	551
FN_THER_DSD	Sum of Age disaggregates	3,537	551
FN_THER_DSD	Aggregated Age: <18	343	
FN_THER_DSD	Aggregated Age: 18+	3,194	
FN_THER_DSD	Sum of Aggregated Age disaggregates	3,537	

### Implementing Mechanism Details

<b>Mechanism ID: 14228</b>	<b>Mechanism Name: Mulu Prevention Program for At-Risk Populations I (Mulu I)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 9,646,246</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	9,646,246

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 14228			
<b>Mechanism Name:</b> Mulu Prevention Program for At-Risk Populations I (Mulu I)			
<b>Prime Partner Name:</b> Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	154,780	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,868,125	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	7,073,341	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	350,000	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	600	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	2,760	
PMTCT_STAT_DSD	By: Number of new positives identified	16	

PMTCT_STAT_DSD	Sum of Positives Status disaggregates	16	
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	99,630	77,957
PP_PREV_DSD	Age/sex: 20-24 Male	19,926	36,497
PP_PREV_DSD	Age/sex: 25-49 Male	39,852	12,177
PP_PREV_DSD	Age/sex: 20-24 Female	19,926	9,296
PP_PREV_DSD	Age/sex: 25-49 Female	19,926	5,225
PP_PREV_DSD	Sum of Age/Sex disaggregates	99,630	77,957
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	55,200	65,714
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	55,200	65,714
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	150,894	169,144
HTC_TST_DSD	By Test Result: Negative	143,349	163,718
HTC_TST_DSD	By Test Result: Positive	7,545	5,426
HTC_TST_DSD	Sum of Test Result disaggregates	150,894	169,144
HTC_TST_DSD	Age/sex: 15-19 Male	15,089	
HTC_TST_DSD	Age/sex: 20-24 Male	15,089	
HTC_TST_DSD	Age/sex: 25-49 Male	60,358	
HTC_TST_DSD	Age/sex: 15-19 Female	15,089	
HTC_TST_DSD	Age/sex: 20-24 Female	15,089	
HTC_TST_DSD	Age/sex: 25-49 Female	30,180	
HTC_TST_DSD	Sum of Age/Sex disaggregates	150,894	

GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	10,955	9,000
GEND_NORM_DSD	By Age: 15-19	2,748	
GEND_NORM_DSD	By Age: 20-24	2,749	
GEND_NORM_DSD	By Age: 25+	5,498	
GEND_NORM_DSD	Sum of Age disaggregates	10,995	
GEND_NORM_DSD	By Sex: Male	6,573	
GEND_NORM_DSD	By Sex: Female	4,382	
GEND_NORM_DSD	Sum of Sex disaggregates	10,955	
GEND_NORM_DSD	By type of activity: Small Group	10,955	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	1,509	
CARE_NEW_DSD	Age/sex: <1 Male	905	
CARE_NEW_DSD	Age/sex: 20-24 Male	305	
CARE_NEW_DSD	Age/sex: 25-49 Male	600	
CARE_NEW_DSD	Age/sex: <1 Female	604	
CARE_NEW_DSD	Age/sex: 20-24 Female	302	
CARE_NEW_DSD	Age/sex: 25-49 Female	302	
CARE_NEW_DSD	Sum of Age/sex disaggregates	3,018	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	231	133
LAB_CAP_DSD	By clinical laboratories	167	133
LAB_CAP_DSD	By Point-of-care testing sites	64	
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	231	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	231	
LAB_CAP_TA	Sum of Site Support Type disaggregates	231	



FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	231	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	231	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	231	
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	231	
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	231	

### Implementing Mechanism Details

<b>Mechanism ID: 14230</b>	<b>Mechanism Name: MULU Prevention Program for At-Risk Populations in Workplace (MULU II)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: World Learning	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,200,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,200,000

### Sub Partner Name(s)

(No data provided.)



### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	14230		
<b>Mechanism Name:</b>	MULU Prevention Program for At-Risk Populations in Workplace (MULU II)		
<b>Prime Partner Name:</b>	World Learning		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	150,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	800,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	2,000,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	250,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention	325,000	267,700

	intervention including the minimum components during the reporting period.		
PP_PREV_DSD	Age/sex: 10-14 Male	3,062	
PP_PREV_DSD	Age/sex: 15-19 Male	18,594	25,711
PP_PREV_DSD	Age/sex: 20-24 Male	27,946	100,343
PP_PREV_DSD	Age/sex: 25-49 Male	95,863	122,271
PP_PREV_DSD	Age/sex: 50+ Male	14,196	
PP_PREV_DSD	Age/sex: 10-14 Female	2,249	
PP_PREV_DSD	Age/sex: 15-19 Female	21,767	2,948
PP_PREV_DSD	Age/sex: 20-24 Female	36,853	8,368
PP_PREV_DSD	Age/sex: 25-49 Female	96,843	8,061
PP_PREV_DSD	Age/sex: 50+ Female	7,627	
PP_PREV_DSD	Sum of Age/Sex disaggregates	325,000	267,702
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	4,800	4,800
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,800	4,800
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	270,000	170,000
HTC_TST_DSD	By Test Result: Negative	267,000	164,020
HTC_TST_DSD	By Test Result: Positive	3,000	1,458
HTC_TST_DSD	Sum of Test Result disaggregates	270,000	165,478
HTC_TST_DSD	Age/sex: 10-14 Male	3,107	
HTC_TST_DSD	Age/sex: 15-19 Male	18,866	
HTC_TST_DSD	Age/sex: 20-24 Male	28,356	



HTC_TST_DSD	Age/sex: 25-49 Male	97,268	
HTC_TST_DSD	Age/sex: 50+ Male	14,404	
HTC_TST_DSD	Age/sex: 10-14 Female	1,600	
HTC_TST_DSD	Age/sex: 15-19 Female	14,218	
HTC_TST_DSD	Age/sex: 20-24 Female	24,073	
HTC_TST_DSD	Age/sex: 25-49 Female	63,127	
HTC_TST_DSD	Age/sex: 50+ Female	4,981	
HTC_TST_DSD	Sum of Age/Sex disaggregates	270,000	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	50	54
LAB_CAP_DSD	By Point-of-care testing sites	50	54
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	50	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	50	
LAB_CAP_TA	Sum of Site Support Type disaggregates	50	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	44	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	100	

### Implementing Mechanism Details

<b>Mechanism ID: 14232</b>	<b>Mechanism Name: Yekokeb Berhan</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Pact, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 8,263,988</b>	
---	--



<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	8,263,988

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 14232			
<b>Mechanism Name:</b> Yekokeb Berhan			
<b>Prime Partner Name:</b> Pact, Inc.			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	7,813,988	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	50,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	300,000	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	60,000	54,676
OVC_ACC_DSD	Sex: Male	30,595	
OVC_ACC_DSD	Sex: Female	29,405	
OVC_ACC_DSD	Sum of Sex disaggregates	60,000	
OVC_ACC_DSD	Age: <1	166	
OVC_ACC_DSD	Age: 1-4	8,010	
OVC_ACC_DSD	Age: 5-9	19,866	
OVC_ACC_DSD	Age: 10-14	19,926	
OVC_ACC_DSD	Age: 15-17	10,608	
OVC_ACC_DSD	Age: 18+	1,424	
OVC_ACC_DSD	Sum of Age disaggregates	60,000	
OVC_ACC_TA	Sum of Sex disaggregates	60,000	
OVC_ACC_TA	Sum of Age disaggregates	60,000	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	455,000	508,375
OVC_SERV_DSD	Sex: Male	218,398	
OVC_SERV_DSD	Sex: Female	236,602	
OVC_SERV_DSD	Sum of Sex disaggregates	455,000	
OVC_SERV_DSD	Age: <1	1,198	
OVC_SERV_DSD	Age: 1-4	27,601	
OVC_SERV_DSD	Age: 5-9	95,701	
OVC_SERV_DSD	Age: 10-14	108,000	
OVC_SERV_DSD	Age: 15-17	67,500	
OVC_SERV_DSD	Age: 18+	155,000	



OVC_SERV_DSD	Sum of Age disaggregates	455,000	
--------------	--------------------------	---------	--

### Implementing Mechanism Details

<b>Mechanism ID: 14267</b>	<b>Mechanism Name: Infrastructure development for health systems strengthening</b>
Funding Agency: State/AF	Procurement Type: USG Core
Prime Partner Name: Regional Procurement Support Office/Frankfurt	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 6,623,727</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	14267
<b>Mechanism Name:</b>	Infrastructure development for health systems strengthening
<b>Prime Partner Name:</b>	Regional Procurement Support Office/Frankfurt



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 14309</b>	<b>Mechanism Name: Strengthening National Response to HIV/AIDS</b>
Funding Agency: USAID	Procurement Type: Umbrella Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 860,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	860,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 14309			
<b>Mechanism Name:</b> Strengthening National Response to HIV/AIDS			
<b>Prime Partner Name:</b> World Health Organization			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	490,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	120,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 14351	<b>Mechanism Name:</b> Capacity Building of Local Organizations
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: National Network of Positive Women Ethiopia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



<b>Total All Funding Sources: 409,200</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	409,200

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 14351</b>			
<b>Mechanism Name: Capacity Building of Local Organizations</b>			
<b>Prime Partner Name: National Network of Positive Women Ethiopia</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	139,200	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	70,000	0

**Implementing Mechanism Indicator Information**



(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 14354</b>	<b>Mechanism Name: Partnership for Supply Chain Management</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Partnership for Supply Chain Management	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 19,368,383</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	19,368,383

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	14354
<b>Mechanism Name:</b>	Partnership for Supply Chain Management
<b>Prime Partner Name:</b>	Partnership for Supply Chain Management



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	3,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	700,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	3,615,015	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	40,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	107,248	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	658,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	11,248,120	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16738</b>	<b>Mechanism Name: Improving Public Health Practices and Service Delivery in the Federal Democratic Republic of Ethiopia with a Focus on HIV, Sexually Transmitted Infections, and Tuberculosis</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Ethiopian Public Health Association	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,526,200</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,526,200

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	156,370
----------------------------	---------

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	16738		
<b>Mechanism Name:</b>	Improving Public Health Practices and Service Delivery in the Federal Democratic Republic of Ethiopia with a Focus on HIV, Sexually Transmitted Infections, and Tuberculosis		
<b>Prime Partner Name:</b>	Ethiopian Public Health Association		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	170,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	90,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1,266,200	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	65	65	Redacted
HRH_PRE	By Graduates: Other	65	65	Redacted
HRH_PRE	Sum of Graduates disaggregated	65	65	Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 16742</b>	<b>Mechanism Name: Comprehensive HIV Prevention, Care and Treatment for the National Defense Force of Ethiopia (NDFE)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Defense Forces of Ethiopia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC



<b>Total All Funding Sources: 2,773,703</b>	
<b>Applied Pipeline Amount: 50,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,773,703

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Gender: GBV	13,706
Focus Area:	Post GBV Care
Sub Area:	Implementation
Food and Nutrition: Policy, Tools, and Service Delivery	27,413
Human Resources for Health	274,132

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	16742		
<b>Mechanism Name:</b>	Comprehensive HIV Prevention, Care and Treatment for the National Defense Force of Ethiopia (NDFE)		
<b>Prime Partner Name:</b>	National Defense Forces of Ethiopia		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	236,028	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HVTB	182,383	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	20,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	50,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	127,300	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	95,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMIN	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	130,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	647,992	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	45,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	40,000	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	72	72	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	103	75	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	72		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	28	25	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	44	47	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	72		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	72	72	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,590	2,590	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	2,875	2,726	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	41	53	Redacted

PMTCT_STAT_DS D	By: Number of new positives identified	62	22	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	103	75	Redacted
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	90,000	76,500	Redacted
PP_PREV_DSD	Total number of people in the target population	200,000	191,250	Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	20,640	2,160	Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	11,306	2,295	Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	44,221	4,976	Redacted
PP_PREV_DSD	Age/sex: 50+ Male	333	69	Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	2,160	10,640	Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	2,295	11,306	Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	8,976	44,721	Redacted
PP_PREV_DSD	Age/sex: 50+ Female	69	333	Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	90,000	76,500	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	9,000		Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	60,000	60,000	Redacted
HTC_TST_TA	By Test Result: Negative	59,220		Redacted
HTC_TST_TA	By Test Result: Positive	780		Redacted
HTC_TST_TA	Sum of Test Result disaggregates	60,000		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	600	5,917	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ	53,400	17,215	Redacted

	PERMISSION ONLY: 15+ Male			
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	600	5,039	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,400	31,829	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	1,200	10,956	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	58,800	49,044	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	60,000	60,000	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	8,202	6,928	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	112		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,712		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	102		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,276		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	8,202		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	2,055	1,015	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	7		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,313		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	7		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	728		Redacted

CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	2,055		Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	2,055		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	800	187	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	73	68	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	103		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	38	54	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	35	14	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	73	68	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	7,433	6,759	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	8	16	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	23	54	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	81	92	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	4,981		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	7	13	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	22	48	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	73	94	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	2,238		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	214	6,759	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	8		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	7		Redacted

TX_CURR_DSD	Aggregated Age/Sex: <15 Male	112		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	4,981		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	102		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,238		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	214		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	7,219		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	7,433		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	15		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,002	962	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	2	4	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	7	12	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	11	13	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	13	6	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	30	5	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	62	18	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	548	552	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	47	31	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	2	3	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	6	9	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	10	11	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	10	6	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	29	13	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	58	92	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	156	175	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	11	12	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,002	962	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	2		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	33		Redacted

TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	687		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	2		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	28		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	254		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,002		Redacted
TX_NEW_DSD	Pregnancy status	28		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	705	822	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	940	968	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	1	4	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	1		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	1		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	1		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	32	31	Redacted
LAB_CAP_DSD	By site support type: Direct Service	32		Redacted

	Delivery (DSD)			
LAB_CAP_DSD	Sum of Site Support Type disaggregates	32		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	32		Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	601	20	Redacted
HRH_PRE	By Graduates: Nurses	415		Redacted
HRH_PRE	By Graduates: Other	161		Redacted
HRH_PRE	Sum of Graduates disaggreagtes	576	20	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	35		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	7,382	6,789	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	8,202	6,928	Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 16749</b>	<b>Mechanism Name: Technical Assistance for the Transition of Comprehensive HIV/AIDS Programs and Medical Education to Ethiopia</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 17,409,161</b>	
<b>Applied Pipeline Amount: 230,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	17,409,161

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Gender: GBV	88,600
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	1,772,700
Food and Nutrition: Policy, Tools, and Service Delivery	177,227
Education	177,227
Condom programming	88,600
Water	88,613
Key Populations: FSW	177,277
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Motor Vehicles: Purchased	550,000



Renovation	1,000,000
------------	-----------

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	16749		
<b>Mechanism Name:</b>	Technical Assistance for the Transition of Comprehensive HIV/AIDS Programs and Medical Education to Ethiopia		
<b>Prime Partner Name:</b>	Columbia University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	1,400,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	672,805	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	260,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	277,485	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	163,200	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	750,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	CIRC	179,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMBL	245,280	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	744,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	90,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	241,991	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	11,500,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	885,400	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	630	1,140	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	688	1,191	Redacted

PMTCT_ARV_DS D	Life-long ART (including Option B+)	600		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	420	400	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	210	740	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	600		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	630	1,140	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	31,149	73,239	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	34,496	77,094	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	494	789	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	194	402	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	688	1,191	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	50	50	Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	10,000	10,000	Redacted
VMMC_CIRC_DS D	By Age: 10-14	3,500	3,275	Redacted

VMMC_CIRC_DS D	By Age: 15-19	3,000	1,756	Redacted
VMMC_CIRC_DS D	By Age: 20-24	2,200	920	Redacted
VMMC_CIRC_DS D	By Age: 25-49	1,200		Redacted
VMMC_CIRC_DS D	By Age: 50+	100	138	Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	10,000	6,089	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	200	6	Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	8,800	7,996	Redacted
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	1,000	1,998	Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	10,000	10,000	Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	10,000	10,000	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	10,500	2,357	Redacted
PP_PREV_TA	Total number of people in the target population	13,125	2,830	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	240,000	313,991	Redacted

HTC_TST_TA	By Test Result: Negative	236,880	309,079	Redacted
HTC_TST_TA	By Test Result: Positive	3,120	4,912	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	240,000	313,991	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	16,800	30,852	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	103,200	89,723	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	19,200	26,281	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	100,800	167,135	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	36,000	57,133	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	204,000	256,858	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	240,000	313,991	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	17,076	18,116	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	615		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	6,519		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	560		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	9,382		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	17,076		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at	3,364	3,939	Redacted

	enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load			
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	73		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,235		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	75		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	1,981		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	3,364		Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	3,364		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	482	1,064	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	688		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	15,220	16,584	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	42	43	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	124	158	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	441	263	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	5,483		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	39	32	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	120	137	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	395	276	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	8,576		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	1,161	16,584	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	8		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART)	60		Redacted

	[CURRENT]			
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	42		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	39		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	607		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	5,483		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	554		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	8,576		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,161		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	14,059		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	15,220		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	81		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,542	3,785	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	15	10	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	46	41	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	74	50	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	100	16	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	53	15	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	111	68	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	980	1,037	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	83	119	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	13	8	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	37	31	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	60	47	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	49	16	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	217	42	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	441	364	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,178	1,880	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	85	41	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,542	3,785	Redacted

TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	15		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	235		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,227		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	13		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	159		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,921		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,542		Redacted
TX_NEW_DSD	Pregnancy status	420	0	Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	69	118	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	69		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	69		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	69		Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	954		Redacted
HRH_PRE	By Graduates: Doctors	208		Redacted
HRH_PRE	By Graduates: Nurses	279		Redacted
HRH_PRE	By Graduates: Midwives	221		Redacted
HRH_PRE	By Graduates: Social service workers	0		Redacted
HRH_PRE	By Graduates: Laboratory professionals	0		Redacted

HRH_PRE	By Graduates: Other	74		Redacted
HRH_PRE	Sum of Graduates disaggreagtes	782		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	69		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	69		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	69		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	69		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	69		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	69		Redacted
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	69		Redacted
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	69		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	15,336	17,708	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO	17,076	18,116	Redacted



	staging) OR CD4 count OR viral load			
--	-------------------------------------	--	--	--

### Implementing Mechanism Details

<b>Mechanism ID: 16750</b>	<b>Mechanism Name: Technical assistance and collaboration with country and regional programs</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 813,600</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	813,600

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	81,360
----------------------------	--------

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 16750</b>
----------------------------



<b>Mechanism Name:</b>	<b>Technical assistance and collaboration with country and regional programs</b>		
<b>Prime Partner Name:</b>	<b>World Health Organization</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	500,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	91,600	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMBL	222,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16751</b>	<b>Mechanism Name: Strengthening Capacity for Laboratory Systems, Strategic Information, and Technical Leadership in Public Health for the National HIV/AIDS Response in Ethiopia</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ethiopian Public Health Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 2,751,800</b>	
<b>Applied Pipeline Amount: 100,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>



GHP-State	2,751,800
-----------	-----------

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Motor Vehicles: Purchased	70,000
Human Resources for Health	285,180

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	16751		
<b>Mechanism Name:</b>	Strengthening Capacity for Laboratory Systems, Strategic Information, and Technical Leadership in Public Health for the National HIV/AIDS		
<b>Prime Partner Name:</b>	Response in Ethiopia Ethiopian Public Health Institute		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	300,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	950,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	601,800	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Treatment	HTXS	900,000	0
-----------	------	---------	---

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	6	10	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	6		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	6		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	6		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	11	10	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	11		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	11		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	11		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 16752</b>	<b>Mechanism Name: Strengthening Local Ownership for the Sustainable Provision of HIV/AIDS Services in the Regional Health Bureaus (Amhara)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Amhara Regional Health Bureau	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 9,434,100</b>	
<b>Applied Pipeline Amount: 100,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	9,434,100

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Condom programming	47,600
Key Populations: FSW	95,340
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Water	47,600
Food and Nutrition: Policy, Tools, and Service Delivery	95,340
Gender: GBV	47,600
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	476,700
Education	95,340



Motor Vehicles: Purchased	585,000
Renovation	1,000,000

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	16752		
<b>Mechanism Name:</b>	Strengthening Local Ownership for the Sustainable Provision of HIV/AIDS Services in the Regional Health Bureaus (Amhara)		
<b>Prime Partner Name:</b>	Amhara Regional Health Bureau		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	1,280,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	300,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	140,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	290,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	271,300	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	110,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	78,800	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	180,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	164,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	850,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,800,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	970,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	3,682	5,517	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	4,444	5,670	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	3,682		Redacted

PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	715	1,868	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	2,967	3,391	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	3,682		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	3,682	5,259	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	249,791	331,919	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	274,825	353,706	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	2,659	3,836	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	1,785	1,665	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	4,444	5,501	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	7,625	11,384	Redacted
PP_PREV_TA	Total number of people in the target population	9,531	13,862	Redacted
HTC_TST_TA	Number of individuals who received	940,000	1,174,310	Redacted

	T&C services for HIV and received their test results during the past 12 months			
HTC_TST_TA	By Test Result: Negative	916,500	1,084,984	Redacted
HTC_TST_TA	By Test Result: Positive	23,500	17,287	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	940,000	1,102,271	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	65,800	92,575	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	404,200	269,136	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	75,200	78,825	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	394,800	501,009	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	141,000	171,400	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	799,000	770,145	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	940,000	941,545	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	143,695	135,373	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,158		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	54,848		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,756		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	78,933		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	143,695		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care	15,776	17,130	Redacted

	during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load			
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	340		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	5,791		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	353		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	9,292		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	15,776		Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	15,776		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	16,000	2,828	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	18,634	16,147	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,712	138	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,712	132	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,111	5,124	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	4,444		Redacted

TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	126,122	127,747	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	344	455	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	1,029	1,528	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	3,715	2,596	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	47,702		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	340	347	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	1,024	1,351	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	3,324	2,694	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	68,644		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	9,776	125,586	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	8		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	58		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	344		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	340	0	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	5,088		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	47,702	0	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	4,688		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	68,644		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	9,776		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	116,346	0	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	126,122	0	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	684	0	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	27,020	17,680	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	119	90	Redacted

TX_NEW_DSD	By Age/Sex: 1-4 Male	359	331	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	580	398	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	649	180	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	398	72	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	836	308	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	7,373	4,375	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	626	504	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	115	76	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	344	247	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	558	349	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	623	182	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	1,634	206	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	3,314	1,586	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	8,855	7,820	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	637	167	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	27,020	16,891	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	119		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,707		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	9,233		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	115		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,640		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	14,440		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	27,020		Redacted
TX_NEW_DSD	Pregnancy status	715		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	41,796	15,424	Redacted

TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	49,486	18,247	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	4	8	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	4		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	4		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	4		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	211	426	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	211		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	211		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	211		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	210		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	129,003	18,268	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and	143,695	135,373	Redacted



	children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load			
--	---	--	--	--

**Implementing Mechanism Details**

<b>Mechanism ID: 16779</b>	<b>Mechanism Name: Technical Assistance for System Development for Accreditation of Laboratories and Implementation of Improved Diagnostic Technologies in Ethiopia</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 100,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	100,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	10,000
----------------------------	--------

**Key Issues**

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b>	16779		
<b>Mechanism Name:</b>	Technical Assistance for System Development for Accreditation of Laboratories and Implementation of Improved Diagnostic Technologies		
<b>Prime Partner Name:</b>	in Ethiopia African Society for Laboratory Medicine		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16798</b>	<b>Mechanism Name: TIMIR Sexual Prevention Program for MARPs/Vulnerable Groups at Civil-Military Interface Settings-Ethiopia</b>		
Funding Agency: DOD	Procurement Type: Grant		
Prime Partner Name: FHI 360			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: No	Managing Agency:		
<b>Total All Funding Sources: 300,000</b>			
<b>Applied Pipeline Amount: 0</b>			
Funding Source	Funding Amount		
GHP-State	300,000		

### Sub Partner Name(s)



(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Condom programming	20,000
Key Populations: FSW	30,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	16798		
<b>Mechanism Name:</b>	TIMIR Sexual Prevention Program for MARPs/Vulnerable Groups at		
<b>Prime Partner Name:</b>	Civil-Military Interface Settings-Ethiopia		
	FHI 360		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	300,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**



<b>Mechanism ID: 16826</b>	<b>Mechanism Name: In school youth HIV prevention</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 16826</b>			
<b>Mechanism Name: In school youth HIV prevention</b>			
<b>Prime Partner Name: FHI 360</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVAB	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	22,500	
PP_PREV_DSD	Age/sex: 15-19 Male	5,062	
PP_PREV_DSD	Age/sex: 20-24 Male	5,062	
PP_PREV_DSD	Age/sex: 15-19 Female	6,188	
PP_PREV_DSD	Age/sex: 20-24 Female	6,188	
PP_PREV_DSD	Sum of Age/Sex disaggregates	22,500	

### Implementing Mechanism Details

<b>Mechanism ID: 16901</b>	<b>Mechanism Name: Strengthening local ownership for sustainable provision of HIV/AIDS services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: SNNPR	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 5,959,800</b>	
<b>Applied Pipeline Amount: 50,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	5,959,800



**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	600,980
Water	30,049
Key Populations: FSW	60,098
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Gender: GBV	30,049
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Food and Nutrition: Policy, Tools, and Service Delivery	60,098
Education	60,098
Condom programming	30,049
Renovation	680,000
Motor Vehicles: Purchased	355,000

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 16901
----------------------------



<b>Mechanism Name:</b> Strengthening local ownership for sustainable provision of HIV/AIDS			
<b>Prime Partner Name:</b> services SNNPR			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	730,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	85,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	175,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	249,400	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	95,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	39,400	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Prevention	HVOP	95,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	430,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	3,450,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	261,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,477	1,802	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,111	1,869	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	1,800		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,117	635	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	683	1,167	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	1,800		Redacted

PMTCT_ARV_DS D	Sum of New and Current disaggregates	1,800	1,802	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	138,121	177,767	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	156,356	187,069	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	868	1,302	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	1,243	575	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	2,111	1,877	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	7,075	7,095	Redacted
PP_PREV_TA	Total number of people in the target population	8,843	8,513	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	500,000	769,322	Redacted
HTC_TST_TA	By Test Result: Negative	493,500	754,894	Redacted
HTC_TST_TA	By Test Result: Positive	6,500	14,239	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	500,000	769,133	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	35,000	75,447	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	215,000	222,808	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	40,000	64,845	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	210,000	406,033	Redacted

	PERMISSION ONLY: 15+ Female			
HTC_TST_TA	Sum of Aggregated Age/Sex <15	75,000	140,292	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	425,000	628,841	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	500,000	769,133	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	41,204	44,934	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,253		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	15,907		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,153		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	22,891		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	41,204		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	12,484	8,446	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	269		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	4,582		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	279	1	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	7,354		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	12,484	1	Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	12,484	1	Redacted

FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	3,500	1,008	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	5,345	3,411	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,530	1,369	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,530	1,369	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,478	1,692	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	2,111		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	778	1,326	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	700	366	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,478	1,692	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	30,196	33,882	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	83	105	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	251	373	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	901	637	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	11,130		Redacted

TX_CURR_DSD	Age/Sex: <1 Female	83	81	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	248	324	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	806	666	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	16,694		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	2,372	33,803	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	83		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	83		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,235		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	11,130		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,137		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	16,694		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,372		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	27,824		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	30,196		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	166		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,840	7,332	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	25	22	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	74	101	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	120	103	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	139	49	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	84	38	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	177	130	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,558	1,992	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	132	222	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	24	21	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	74	62	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	120	99	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	130	49	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	360	77	Redacted

TX_NEW_DSD	By Age/Sex: 20-24 Female	731	695	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,952	3,567	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	140	103	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	5,840	7,330	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	25		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	358		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,951		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	24		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	348		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,183		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	5,840		Redacted
TX_NEW_DSD	Pregnancy status	1,117		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,107	3,786	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	5,134	4,519	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	3	12	Redacted

LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	3		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	3		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	3		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	102	296	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	102		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	102		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	102		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	103		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	37,004	41,834	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	41,204	44,934	Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 16912</b>	<b>Mechanism Name: Health Finance and Governance</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
---------	------------------

<b>Total All Funding Sources: 1,700,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,700,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	16912		
<b>Mechanism Name:</b>	Health Finance and Governance		
<b>Prime Partner Name:</b>	Abt Associates		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	1,700,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**



<b>Mechanism ID: 16927</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 16930</b>	<b>Mechanism Name: Household Economic Strengthening</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 250,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	250,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information



<b>Mechanism ID: 16930</b>			
<b>Mechanism Name: Household Economic Strengthening</b>			
<b>Prime Partner Name: FHI 360</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	250,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16973</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 16974</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 16975</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 17000</b>	<b>Mechanism Name: Strengthening Local Ownership for the Sustainable Provision of Comprehensive HIV/AIDS Services by the Health Bureau of Tigray Regional State of the Federal Democratic Republic of Ethiopia under the President's Emergency Plan for AIDS Relief (PEPFAR)</b>
----------------------------	--



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Tigray Regional Health Bureau	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 5,450,087</b>	
<b>Applied Pipeline Amount: 50,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	5,450,087

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Water	27,500
Key Populations: FSW	55,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Human Resources for Health	550,000
Gender: GBV	27,500
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Food and Nutrition: Policy, Tools, and Service Delivery	55,000
Education	55,000



Condom programming	27,500
Motor Vehicles: Purchased	397,308
Renovation	252,510

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17000		
<b>Mechanism Name:</b>	Strengthening Local Ownership for the Sustainable Provision of Comprehensive HIV/AIDS Services by the Health Bureau of Tigray		
<b>Prime Partner Name:</b>	Regional State of the Federal Democratic Republic of Ethiopia under the President's Emergency Plan for AIDS Relief (PEPFAR)		
<b>Prime Partner Name:</b>	Tigray Regional Health Bureau		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	830,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	95,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	110,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	101,700	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Governance and Systems	OHSS	88,787	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMBL	26,600	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMIN	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	140,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	70,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	218,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	3,250,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	320,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT)	2,032	1,102	Redacted

	during pregnancy and delivery			
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,258	1,146	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	2,032		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	768	379	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,264	723	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	2,032		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	2,032	1,102	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	171,553	86,728	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	177,498	91,495	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	1,355	810	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	903	347	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	2,258	1,157	Redacted
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	5,100	634	Redacted
PP_PREV_TA	Total number of people in the target population	6,375	760	Redacted

HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	300,000	361,754	Redacted
HTC_TST_TA	By Test Result: Negative	292,500	356,082	Redacted
HTC_TST_TA	By Test Result: Positive	7,500	5,672	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	300,000	361,754	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	21,000	35,505	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	129,000	103,905	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	24,000	30,240	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	126,000	192,104	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	45,000	65,745	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	255,000	296,009	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	300,000	361,754	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	36,862	40,688	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,395	21	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	14,000	184	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,319	21	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	20,148	301	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	36,862	527	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and	6,585	4,746	Redacted

	children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load			
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	142		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	2,417		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	147		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	3,879		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	6,585		Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	6,585		Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	9,926	1,233	Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	9,926	5,117	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	498	799	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	498	805	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,581	1,036	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive	2,258		Redacted

	women at entry into PMTCT)			
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	831	823	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	750	213	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,581	1,036	Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	39,876	38,088	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	97	145	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	282	505	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	995	860	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	14,509		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	90	116	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	280	446	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	930	903	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	22,693		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	2,674	38,088	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	97		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	90		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,374		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	14,509		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,300		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	22,693		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,674		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	37,202		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	39,876		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	187		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	7,335	5,232	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	30	32	Redacted

TX_NEW_DSD	By Age/Sex: 1-4 Male	91	112	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	145	133	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	163	56	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	101	17	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	212	85	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,868	1,333	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	159	156	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	29	25	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	85	81	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	140	119	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	155	55	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	470	54	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	954	476	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,550	2,446	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	183	52	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	7,335	5,232	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	30		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	429		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,340		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	29		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	409		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	4,157		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	7,335		Redacted
TX_NEW_DSD	Pregnancy status	768		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,198	4,563	Redacted

TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	6,497	5,432	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	2	12	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	2		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	2		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	2		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	100	260	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	100		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	100		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	100		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	103		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	33,086	41,422	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and	36,862	40,688	Redacted



	children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load			
--	---	--	--	--

**Implementing Mechanism Details**

<b>Mechanism ID: 17265</b>	<b>Mechanism Name: USAID DELIVER</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: John Snow, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 550,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	550,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17265
----------------------	-------



<b>Mechanism Name:</b>	<b>USAID DELIVER</b>		
<b>Prime Partner Name:</b>	<b>John Snow, Inc.</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	50,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	500,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17271</b>	<b>Mechanism Name: Capacity Building of Local Organizations</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Ethiopian Society of Sociologists, Social Workers and Anthropologists	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 200,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	200,000

### Sub Partner Name(s)

(No data provided.)



### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 17271			
<b>Mechanism Name:</b> Capacity Building of Local Organizations			
<b>Prime Partner Name:</b> Ethiopian Society of Sociologists, Social Workers and Anthropologists			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	50,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	1,870	1,820
HRH_PRE	By Graduates: Social service workers	1,870	1,820
HRH_PRE	Sum of Graduates disaggreagtes	1,870	1,820

### Implementing Mechanism Details

<b>Mechanism ID:</b> 17272	<b>Mechanism Name:</b> Capacity Building of Local
----------------------------	---



	<b>Organizations</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Hope for Children	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 192,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	192,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17272		
<b>Mechanism Name:</b>	Capacity Building of Local Organizations		
<b>Prime Partner Name:</b>	Hope for Children		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	192,000	0



## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID: 17635</b>	<b>Mechanism Name: Challenge TB</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: KNCV Tuberculosis Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 778,718</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	778,718

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 17635
----------------------------



<b>Mechanism Name:</b>	Challenge TB		
<b>Prime Partner Name:</b>	KNCV Tuberculosis Foundation		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	778,718	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17641</b>	<b>Mechanism Name: Advancing Partners and Communities (APC)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 818,010</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	818,010

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)



### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 17641			
<b>Mechanism Name:</b> Advancing Partners and Communities (APC)			
<b>Prime Partner Name:</b> John Snow Inc (JSI)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	818,010	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 17746	<b>Mechanism Name:</b> Peace Corps/Ethiopia Volunteer Trainings and Small Grants
Funding Agency: PC	Procurement Type: Cooperative Agreement
Prime Partner Name: Peace Corps Volunteers	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 0	
<b>Applied Pipeline Amount:</b> 235,161	
Funding Source	Funding Amount
GHP-State	0



**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 17746			
<b>Mechanism Name:</b> Peace Corps/Ethiopia Volunteer Trainings and Small Grants			
<b>Prime Partner Name:</b> Peace Corps Volunteers			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 17824	<b>TBD:</b> Yes
<b>REDACTED</b>	



### Implementing Mechanism Details

Mechanism ID: 17825	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 17843	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 17856	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 17908	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 17953	TBD: Yes
REDACTED	



**Agency Information - Costs of Doing Business**  
**U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		267,958		267,958	0
ICASS		1,044,345		1,044,345	0
Management Meetings/Professional Development		309,423		309,423	0
Non-ICASS Administrative Costs		62,538		62,538	0
Staff Program Travel		195,454		195,454	0
USG Staff Salaries and Benefits		3,546,501		3,546,501	0
<b>Total</b>	<b>0</b>	<b>5,426,219</b>	<b>0</b>	<b>5,426,219</b>	<b>0</b>

**U.S. Department of Defense**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
ICASS		0		0	30,000
Indirect Costs		0		0	12,000
Institutional Contractors				0	0
Staff Program				0	33,000



Travel					
USG Staff Salaries and Benefits				0	45,000
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>120,000</b>

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		1,302,800		1,302,800	0
Computers/IT Services		588,000		588,000	0
ICASS		1,600,000		1,600,000	0
Institutional Contractors	0	558,000		558,000	0
Management Meetings/Professional Development		59,300		59,300	270,000
Non-ICASS Administrative Costs		18,600		18,600	340,000
Non-ICASS Motor Vehicles	0			0	0
Staff Program Travel		262,500		262,500	250,000
USG Renovation		0		0	0
USG Staff Salaries and Benefits	2,787,500	1,854,700		4,642,200	1,140,000
<b>Total</b>	<b>2,787,500</b>	<b>6,243,900</b>	<b>0</b>	<b>9,031,400</b>	<b>2,000,000</b>



### U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
ICASS		105,000		105,000	0
Institutional Contractors		30,000		30,000	0
Management Meetings/Professional Development		25,000		25,000	0
Non-ICASS Administrative Costs		25,000		25,000	0
Staff Program Travel		40,000		40,000	0
USG Staff Salaries and Benefits		409,000		409,000	0
<b>Total</b>	<b>0</b>	<b>634,000</b>	<b>0</b>	<b>634,000</b>	<b>0</b>

### U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Institutional Contractors				0	0
Non-ICASS Administrative Costs		0		0	286,388
Non-ICASS Motor Vehicles		0		0	16,000
Peace Corps				0	904,271



Volunteer Costs					
Staff Program Travel		0		0	87,689
USG Staff Salaries and Benefits		0		0	361,514
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1,655,862</b>